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Abstract 
Cannabinoid CB1 receptor (CB1R) transmission within the meso-corticolimbic system 
plays an important role in forming associative memories, and processing both positive 
and negative experiences. Opiates generally produce potent rewarding effects and 
previous evidence suggests that CB1 transmission may modulate the neural reward 
circuitry involved in opiate reward processing. The ventral tegmental area (VTA), medial 
prefrontal cortex (mPFC), basolateral amygdala (BLA), and Nucleus Accumbens (NAc) 
are all implicated in opiate-reward processing, contain high levels of CB1 receptors, and 
are all modulated by dopamine (DA). Although, CB1 transmission within these areas has 
been heavily implicated in associative memory and learning, the potential effects of 
CB1R modulation on these neural regions in regards to opiate related motivational 
information are not currently understood. Using a combination of unbiased conditioned 
place preference (CPP) paradigm and pharmacological manipulation, we examined the 
role of CB1 transmission within these neural circuitries in relation to opiate reward 
processing.  
We report that activation or inhibition of CB1 transmission within the mPFC and BLA 
bidirectionally regulates the motivational valence of opiates; whereas CB1 activation 
switched morphine reward signaling into an aversive stimulus, blockade of CB1 
transmission potentiated the rewarding properties of normally sub-reward threshold 
conditioning doses of morphine. Both of these effects were dependent upon DA 
transmission. Furthermore, CB1-mediated intra-mPFC opiate motivational signaling is 
mediated through a μ-opiate receptor-dependent reward pathway, or a κ-opiate receptor-
dependent aversion pathway, directly within the ventral tegmental area. In contrast, CB1-
mediated intra-BLA opiate motivational signaling is mediated through the NMDA 
transmission in the shell region of NAc (NASh). Finally, using multi-unit in 
vivo electrophysiological recordings in the NASh, we report that the ability of intra-BLA 
CB1R modulation to control opiate reward salience and motivational valence is 
associated with distinct reward or aversion neuronal activity patterns and bi-directional 
regulation of intra-NASh fast-spiking interneurons vs. medium spiny neurons. Our results 
provide evidence for a novel CB1 mediated motivational valence switching mechanism 
within the mPFC, and BLA, controlling dissociable subcortical reward and aversion 
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pathways. Lastly, we report that CB1 mediated reward is localized to the CB1R’s 
located in the posterior region of the VTA. 
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1 General Introduction: Cannabinoids, Opiates, and the Reward 
Circuitry 
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1.1 THE ENDOCANNABINOID SYSTEM 
In mammalians, the endocannabinoid system is crucial in maintaining health and 
chemical equilibrium within the body. Endogenous cannabinoids and the receptors they 
bind to, are found throughout the entire body. The endocannabinoid system enables 
communication, modulation and coordination between various cell types and receptors. 
The two major cannabinoid receptors (CBRs) are CB1 and CB2 cannabinoid receptor 
(CB1R and CB2R respectively). The CBRs are a G-protein coupled, seven trans-
membrane domain receptors that are activated by both endogenous and exogenous 
cannabinoids (Console-Bram, Marcu, & Abood, 2012). The activation of CB1 or CB2 
receptors generally blocks adenyl cyclase, and hence prevents signaling through cyclic 
AMP. The two most widely researched endocannabinoid are 2-arachidonoylglycerol (2-
AG) and anandamide, that have been shown to function as retrograde messengers, where 
they are synthesized and released by postsynaptic dendritic cell bodies and activate 
CB1Rs located in the presynaptic axon terminals (Marsicano & Lafenetre, 2009). 
Activation of CB1Rs then modulates signaling by reducing the amount of 
neurotransmitter released, and the overall effect is dependent on the neurotransmitter 
secreted by the specific cell type. CB1Rs are distributed throughout the central nervous 
system (CNS) and are associated with learning, emotional behaviour, and linked to food 
intake and obesity (Chaperon, Soubrié, Puech, & Thiébot, 1998; Martin, Ledent, 
Parmentier, Maldonado, & Valverde, 2002; Osei-Hyiaman, Harvey-White, Batkai, & 
Kunos, 2006; Boyd, 2006). Conversely, CB2Rs are predominantly abundant in the 
peripheral nervous system (PNS), most notably in the immune and hematopoietic cells 
(Pertwee, 1997; Osei-Hyiaman et al., 2006). For the purpose of this study we will be 
focusing on the CB1Rs, as they are primarily present in the brain.  
1.1.1 Role of CB1 Receptor in Emotional Processing 
A critical aspect of functional health in one’s daily life is to present cognitive competence 
and form appropriate responses to the vast array of incoming sensory information from 
their surroundings. In order to successfully form coordinated responses, the human brain 
must assess the emotional valance of the incoming sensory stimuli, which requires the 
formation of learned associative memories between the stimulus and the environmental 
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cues (Laviolette & Grace, 2006). Both animal models and human studies have shown that 
activation of CB1Rs can lead to pronounced effects in associative learning emotional 
processing. The cannabinoid system as mediated by the activation of CB1Rs have shown 
to alter emotional behaviour and participate in both learning and memory processes 
(Martin et al., 2002). Furthermore, CB1R transmission has been implicated to strongly 
modulate the emotional valence of both rewarding and aversive experiences (Laviolette 
& Grace, 2006). 
Although the CB1Rs are highly localized to the brain, they are not uniformly distributed 
in the CNS. They are densest in areas responsible for cognition, learning, and memory 
such as the medial prefrontal cortex (mPFC), basolateral amygdala (BLA), ventral 
tegmental area (VTA), and nucleus accumbens (Tsou et al., 1998; Fattore et al., 2007; 
Katona et al., 2001; Fattore et al., 2007; Marsicano & Lafenetre, 2009). Activation of 
CB1Rs within both the mPFC and BLA have shown to strongly potentiate the emotional 
salience of normally non-salient events (Tan et. al., 2010, 2014). Furthermore, fear 
conditioning studies have shown that inhibiting the CB1R with systemic injections of 
AM 251 (CB1R inverse agonist) in Long-Evans rats resulted in deficits in contextual 
learning and memory processing (Arenos, Musty, & Bucci, 2006). Moreover, previous 
research involving pairing of a neutral stimuli (an olfactory cue) with an emotionally 
salient stimuli (a mild foot shock) have shown that activating CB1Rs with WIN 55,212-2 
(synthetic CB1R agonist) in the mPFC, potentiated emotional learning in animals. In 
contrast, blockade of CB1Rs with AM 251 in the mPFC led to inhibition of emotional 
learning, as the animals response to the olfactory cue was significantly downregulated 
(Laviolette & Grace, 2006). These findings outline the key role that CB1Rs play in 
associative learning and processing emotional salience in the mesolimbic pathway. 
1.2 THE MESOLIMBIC REWARD PATHWAY 
The mesolimbic reward pathway is the dopaminergic (DAergic) circuitry in the brain. It 
is a bundle of DAergic fibers that originate from the VTA and innervate higher level 
limbic structures including mPFC, BLA, and NAc (Gardner, 2005; Grace, Floresco, 
Goto, & Lodge, 2007; Ikemoto, 2007). Dopamine (DA) receptors are highly expressed in 
the VTA and play a crucial role in reward-related leaning, and processing emotional and 
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motivational information ( Wise, 2004; Volkow, Wang, & Baler, 2011). Previous 
research has shown that DA is an integral component of stimulus-reward learning and 
processing the salience of sensory cues (Berridge & Robinson, 1998; Flagel et al., 
2011a). 
A vast array of pharmacological data over the years has indicated the existence of a 
functional interaction between CB1 and DA receptors. Modulation of CB1Rs within the 
mesolimbic circuitry has shown to play a significant role is DAergic transmission 
(Hermann, Marsicano, & Lutz, 2002). Activation of CB1Rs in the mPFC by exogenous 
cannabinoids have been shown to significantly increase extracellular DA levels, and 
decrease GABA (M Pistis et al., 2002). Similarly, single cell electrophysiological 
recordings in rats, demonstrated a profound increase in DA firing levels in the VTA, 
following the administration of a CB1R agonist (French, Dillon, & Wu, 1997; French, 
1997). Hence, it is evident that the endocannabinoid system plays a central role in 
modulating DA levels in the CNS. 
The components of the meso-corticolimbic pathway (as discussed below) consist of the 
VTA-PFC-BLA-NAc circuitry, and they are highly interconnected to one another (see 
Fig.1.1). 
1.2.1 Ventral Tegmental Area 
The ventral tegmental area (VTA) is part of the midbrain and it is the main site of DA 
neurons. It’s a central component of the reward circuitry, and crucial for associative 
learning. The VTA sends DAergic efferent to the mPFC, BLA, and NAc, forming the DA 
cycle. Besides DA, the VTA contains other important receptors such as opiate receptors, 
CB1Rs, and GABA neurons. Rewarding stimuli such as drugs of abuse often target this 
area, altering DA levels and hence distorting emotional regulation. Studies involving 
neuropsychiatric disorders such as ADHD (low levels of DA) and schizophrenia (high 
levels of DA) often show altered DA activity levels (Kalivas, 1993). Due to the 
significance of DA transmission throughout the CNS, and the widespread dopaminergic 
projections of the VTA, the integrity of this neural structure is crucial to proper brain 
function. 
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1.2.2 Medial Prefrontal Cortex 
The medial prefrontal cortex (mPFC) lies anterior to the frontal lobe and is involved in 
cognition, executive function, and coding of emotional learning. It is rich with CB1Rs 
and highly implicated in cue-induced associative learning and memory. Pharmacological 
manipulation of the CB1Rs in the mPFC with synthetic CB1R agonist resulted in the 
extinction of fear memories, whereas blockade of CB1Rs in the mPFC potentiated cue-
induced fear memory (Lin, Mao, Su, & Gean, 2009). Furthermore, activation of CB1Rs 
have shown to increase DAergic transmission in the mPFC, while inhibiting CB1Rs has 
shown the opposite effect (Diana, Melis, & Gessa, 1998). In addition, disturbances in the 
mPFC CB1 activities have been shown to be implicated in addiction models and 
associated with neuropsychiatric disorders such as schizophrenia. 
1.2.3 Basolateral Amygdala 
The basolateral amygdala (BLA) is rich in CB1Rs, processes emotionally salient stimuli, 
and is involved in encoding and retrieval of reward related memories and consolidation 
of memory for a variety of tasks such as contextual fear conditioning, taste aversion, and 
inhibitory avoidance (Campolongo et al., 2009; LaLumiere & Nawar, 2005; McGaugh, 
2000). Memory consolidation refers to the stabilization of an item in long-term memory, 
and it is a necessity in carrying out normal daily activities.  
The BLA is a crucial structure in encoding emotional memories and modulating neuronal 
plasticity related to associative learning. Patch clamp recordings in rats have 
demonstrated that activation of CB1Rs in the BLA with synthetic CB1 agonist, 
modulates GABAergic synaptic transmission (Katona et al., 2001).  Furthermore, CB1 
agonist has shown to lower the overall excitability of efferent neurons in the BLA (Marco 
Pistis et al., 2004). Lesion studies in the BLA, indicate an impairment in memory 
acquisition during spatial memory tasks in rats (Maren, 1999; Roozendaal, Portillo-
Marquez, & McGaugh, 1996). Taken together, it is evident that the BLA plays an 
important role in learning and memory. 
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1.2.4 Nucleus Accumbens 
The nucleus accumbens (NAc) plays a vital role in the reward circuitry, contains high 
levels of both CB1 and DA receptors and it is a key component in consolidation of 
learning memory. For example, studies have shown that early consolidation of 
instrumental learning, such as lever pressing in rats require protein synthesis in the NAc. 
Inhibition of these processes in the NAc, resulted in a disruption of memory 
consolidation in the animals (Hernandez, Sadeghian, & Kelley, 2002; Salamone, Correa, 
Farrar, & Mingote, 2007). Furthermore, cue-induced reward during classical conditioning 
in rats showed a significant increase in DA levels in the NAc during the early phases of 
memory consolidation (Day, Roitman, Wightman, & Carelli, 2007). In addition CB1 has 
shown to modulate DA levels in in the NAc. While activation of CB1Rs by a synthetic 
agonist (WIN 55,212-2) in rats have shown to boost DA release in the NAc, inhibition of 
CB1Rs in the NAc have shown to suppress ethanol self administration in male adult rats 
(Malinen & Hyytia, 2008; Sperlagh, Windisch, Ando, & Sylvester Vizi, 2009).   
The NAc consists of two distinct areas: shell (NASh) and core (NACo) that serve 
different functions. These regions will be explored and discussed in Chapter 3. 
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1.3 CANBIS AND OPIATES 
Cannabis, also known as marijuana, is the most commonly used illicit drug in Canada 
with nearly half of the population (45%) reportedly having used marijuana at least once 
in their lifetime. Although the acute symptoms of light marijuana use often result in short 
term attention and executive function deficits, the chronic symptoms in heavy marijuana 
users can lead to neuropsychological effects and particularly deficits in working memory. 
THC, the active component in marijuana exerts its effect through the brains CB1 
cannabinoid system. 
In accordance to the Canadian Pain Society, chronic pain affects 1 in every 5 people in 
Canada. The most common prescription for chronic pain is opiates, which have various 
side effects such as nausea, sedation, dependence and addiction. In recent years, there is a 
growing body of evidence suggesting the use of medical marijuana in conjunction with 
opiates in the treatment of chronic pain. With both substances having specific side 
effects, it is very important to explore the interaction of cannabis and opiates. 
Opiate addiction studies have shown a disruption in the brains leaning and memory 
system/mesolimbic pathway (Hyman, Malenka, & Nestler, 2006). Activation of CB1Rs 
with THC, and μ-opioid receptors with morphine, have both shown to increase the 
neuronal activity of midbrain DA neurons. Furthermore, μ-opioid receptor signaling is 
attenuated by CB1 agonist (Rios, Gomes, & Devi, 2006). Studies involving male Wistar 
rats, indicated that administration of synthetic CB1 antagonist elicited withdrawal 
symptoms in morphine dependent animals (M Navarro et al., 1998), blocked heroin self-
administration and place conditioning in rats and morphine self-administration in mice 
(Chaperon et al., 1998; Fattore et al., 2007; M Navarro et al., 2001). Furthermore, micro-
infusions of CB1 agonist in the NAc and PFC, have shown to attenuate heroin seeking 
behaviour (Alvarez-Jaimes, Polis, & Parsons, 2008). Hence, it is evident that a functional 
interaction between DA, CB1 and opioid receptors exist, and exploring this interaction 
will aid to better understanding these substances, and their role in learning and memory. 
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1.4 RATIONALE 
Although there is a growing body of research indicating the functional interaction 
between cannabinoid, dopamine and opiate receptors, the specific modulatory 
mechanisms and pathways of CB1 transmission within the mesolimbic pathway are not 
well understood.  Given CB1 transmission plays a crucial role in reward related learning 
and memory and is highly implicated in both addiction models and neuropsychiatric 
disorders, this study will aid in deciphering the specific neural pathways involved.  
1.5 HYPOTHESIS 
Activation or inhibition of CB1R transmission in the medial prefrontal cortex and 
basolateral amygdala will modulate DA signaling in the ventral tegmental area and 
nucleus accumbens pathway, thereby controlling the processing of opiate related 
motivational information, and associative learning memory. 
1.5.1 Objectives 
1. Investigate the specific role of CB1 receptor transmission in the mPFC in 
relation to opiate reward memory, by examining the mPFCVTA neuronal 
pathway using an unbiased conditioned place preference paradigm. 
2. Investigate the potential role of CB1 receptor transmission in the BLA during 
the encoding and recall phases of opiate reward conditioning, by employing 
both a conditioned place preference paradigm and real time in vivo 
electrophysiological recordings. 
3. To characterize the location of CB1 and DA receptors involved during 
cannabinoid related reward in the anterior versus posterior VTA, using intra-
VTA microinfusions of synthetic cannabinoid agonist and antagonist. 
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Chapter 2 
 
2 Cannabinoid transmission in the prelimbic cortex bi-
directionally controls opiate reward and aversion signaling 
through dissociable kappa versus μ-Opiate receptor 
dependent mechanisms1 
 
 
 
 
 
 
 
 
 
 
                                                 
1
 This chapter has been adapted from the published journal article: Ahmad T, Lauzon NM, de Jaeger X, 
and Laviolette, SR. (2013). Cannabinoid transmission in the prelimbic cortex bidirectionally controls opiate 
reward and aversion signaling through dissociable kappa versus μ-Opiate receptor dependent mechanisms. 
Journal of Neuroscience; 33(39): 15642-15651  
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2.1 INTRODUCTION 
In the mammalian brain, cannabinoid CB1 receptor and mesolimbic dopamine (DA) 
transmission functionally interact with opiate-receptor substrates during the processing of 
motivationally salient learning and memory (Tanda et al., 1997; Rodríguez De Fonseca et 
al., 2001). The interconnected ventral tegmental area (VTA) and medial prefrontal cortex 
(mPFC) contain high levels of CB1 receptors. CB1 receptor transmission within these 
regions can potently modulate rewarding and aversive motivational behaviors and 
memory formation (Laviolette and Grace, 2006; Zangen et al., 2006; Tan et al., 2010). 
For example, modulation of CB1 transmission within the prelimbic cortical (PLC) 
division of the mPFC, increases the emotional salience of fear-related stimuli (Laviolette 
and Grace, 2006; Tan et al., 2010). In addition, considerable evidence demonstrates 
functional interactions between CB1 transmission and subcortical DAergic signaling. For 
example, Δ-9-tetrahydrocannabinol (THC) increases glutamate levels within the mPFC 
and activates downstream DAergic neuronal activity in the mesolimbic pathway (Diana 
et al., 1998; Pistis et al., 2001, 2002). Furthermore, in vivo extracellular recording studies 
within the VTA have demonstrated that CB1 receptor activation increases the 
spontaneous activity of subcortical DA neuronal populations (French et al., 1997). 
Although the euphorigenic effects of opiate-class drugs are well established, similar to 
many other drugs of abuse, opiates also possess aversive stimulus properties (Bechara 
and van der Kooy, 1987). The VTA serves as a critical neural region for the processing of 
opiate-related motivational information (Bozarth and Wise, 1981; Laviolette et al., 2004). 
Within the VTA, opiate-related motivational processing is mediated via heterogeneous 
opiate-receptor populations. Thus, whereas opiates primarily produce rewarding effects 
via functional interactions with μ-opiate receptor (MOR) substrates (Gysling and Wang, 
1983; Johnson and North, 1992), activation of κ-opiate receptor (KOR) subtypes is linked 
to the aversive stimulus effects of opioids (Bechara and van der Kooy, 1987; Shippenberg 
and Elmer, 1998; Davis et al., 2009). Anatomically, MOR-sensitive substrates in the 
VTA predominantly project to the basolateral nucleus of the amygdala (BLA) whereas 
KOR-sensitive neuronal substrates predominantly project to the nucleus accumbens 
(NAc; Ford et al., 2006), suggesting a functional segregation within opiate-dependent 
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motivational signaling originating from the VTA. Furthermore, efferents from the mPFC 
to VTA neuronal populations modulate subcortical DA transmission within the 
mesolimbic pathway, including via direct inputs to DAergic neurons within the VTA 
(Carr and Sesack, 2000a). Nevertheless, how CB1 transmission within the mPFC may 
modulate opiate-related motivational information through interactions with subcortical 
DA substrates is not currently known. Using an unbiased conditioned place preference 
(CPP) procedure, we examined how pharmacological modulation of CB1 transmission 
specifically within the PLC division of the mPFC may influence opiate-related reward 
learning and memory processing. We report that intra-PLC modulation of CB1 receptor 
transmission bidirectionally controls the motivational valence of opiate-related behavioral 
conditioning. Whereas CB1 receptor activation switched the motivational valence of 
morphine from rewarding to strongly aversive, pharmacological blockade of intra-PLC 
CB1 receptor transmission strongly increased the reward salience of normally sub-reward 
threshold conditioning doses of morphine. Furthermore, we demonstrate that intra-PLC 
CB1 transmission bidirectionally controls opiate motivational valence through 
dissociable MOR versus KOR-dependent substrates, directly within the VTA. 
2.2  MATERIALS AND METHODS 
2.2.1 Animals and Surgery 
All experimental procedures were performed in accordance with Institutional, Federal, 
and Provincial Animal Care guidelines. Adult male Sprague Dawley rats (350–400 g; 
Charles River Canada) were anesthetized with an intraperitoneal injection of a ketamine 
(80 mg/ml)-xylazine (6 mg/kg) mixture, and placed in a stereotaxic device. For intra-PLC 
microinfusions, two stainless steel guide cannulae (22 gauge) were implanted into the 
PLC division of the mPFC using the following coordinates (15° angle): from bregma, 
anteroposterior (AP) +2.9 mm, lateral (LAT) ±1.9 mm, ventral (V) −3.0 mm from the 
dural surface (Laviolette and Grace, 2006). For experiments involving intra-PLC and 
intra-VTA microinfusions, rats received two additional cannulae implanted in the VTA 
using the following coordinates (10° angle): from bregma, AP −5.0 mm, LAT ±2.3 mm, 
and V −8.0 mm from the dural surface. Dental acrylic and jeweler's screws were used to 
secure the cannulae to the skull surface. 
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2.2.2 Drug Treatments 
The highly selective CB1 agonist (WIN 55,212-2; Tocris Bioscience) or antagonist 
(AM251; Tocris Bioscience) were first dissolved in dimethyl sulfoxide then diluted in 
physiological saline (pH, 7.4). Bilateral microinfusions were performed over a period of 
1 min via plastic tubing connected to a 1 μl Hamilton microsyringe. All microinfusions 
consisted of a total volume of 0.5 μl. Injectors were left in place for an additional 1 min 
to ensure adequate diffusion of the drug from the injector tip. The μ-opioid receptor 
antagonist cyprodime hydrochloride (Tocris Bioscience) and κ-opioid receptor antagonist 
nor-binaltorphimine dihydrochloride (Tocris Bioscience) were dissolved in physiological 
saline, pH 7.4, and micro-infused bilaterally intra-VTA (50 and 500 ng/0.5 μl). Morphine 
sulfate (Macfarland-Smith) and the broad-spectrum DA receptor antagonist α-
flupenthixol hydrochloride (α-flu; Tocris Bioscience) were dissolved in physiological 
saline. For all experiments involving a pharmacological pretreatment, rats received 
pretreatments before both saline and morphine conditioning trials. This built-in 
experimental control mechanism controls for any confounds from potential motivational 
effects of pretreatment drugs. For CPP conditioning, two doses of morphine were used: a 
supra-reward threshold dose (5.0 mg/kg, i.p.) that produces robust CPP, and a sub-reward 
threshold dose (0.05 mg/kg, i.p.) that normally fails to produce a significant CPP (Bishop 
et al., 2011; Lintas et al., 2012). Systemic morphine was administered immediately after 
intra-cranial micro-infusions. For DA antagonist treatment, animals received 0.8 mg/kg 
i.p. α-flu 2.5 hours before conditioning. This dose and time course of α-flu produces no 
motivational effects in and of itself. 
2.2.3 Place Conditioning Procedure 
An unbiased, fully counterbalanced CPP procedure was used, as described previously 
(Bishop et al., 2011; Lintas et al., 2012). Briefly, saline or morphine (systemic or intra-
VTA) was paired with one of two environments which differed in terms of color, texture, 
and smell. Following recovery from surgery, rats were randomly assigned to an 
experimental group. All rats were exposed to a preconditioning phase where they were 
placed into a motivationally neutral gray box for 20 min. The following day, the 8 d 
conditioning phase was commenced. One conditioning environment was white with a 
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wire-mesh floor covered in woodchips. The alternate environment was black with a 
smooth Plexiglas floor wiped down with 2% acetic acid immediately before the animal 
was placed into it. Experimental treatments were counterbalanced such that each animal 
was randomly assigned to receive morphine in either the white or the black environment 
and vice versa when receiving saline. As previously reported, rats displayed no baseline 
preference for either of these environments. During conditioning, rats receive an equal 
number of morphine-environment versus saline-environment pairings. Therefore, over 
the 8 d procedure rats receive four 30 min morphine-environment pairings and four 30 
min saline-environment pairings. During testing, rats are placed on a narrow gray zone 
separating the two test environments and times spent in each environment are digitally 
recorded and scored separately for each animal over a 10 min test session. All rats are 
tested in a drug free state. 
2.2.4 Histology 
After completion of experiments, rats were anesthetized with an overdose of euthanyl 
(sodium pentobarbitol; 240 mg/kg, i.p.) and perfused with isotonic saline followed by 
10% formalin. Brains were extracted, sliced at 40 μm, and stained with Cresyl Violet to 
allow for histological analysis of injection sites. Injector placements were confirmed 
using light microscopy, and rats with misplaced guide cannulae were excluded from 
analysis. 
2.2.5 Data Analysis 
Data were analyzed with either a two-way ANOVA or Student's t tests where 
appropriate. Post hoc analyses were performed with Newman–Keuls and Fisher's least 
significant difference test. 
2.3 RESULTS 
2.3.1 Intra-mPFC and VTA histological analysis 
Histological analysis indicated microinfusion injector cannula placements to be 
bilaterally localized within the anatomical boundaries of the mPFC and VTA region, as 
determined by the Atlas of Paxinos and Watson (1986). In Figure 2.1A, we present a 
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microphotograph showing a representative injector placement within the PLC division of 
the mPFC. In Figure 2.1B, we present a schematic illustration showing representative 
intra-mPFC bilateral cannulae placements along the rostral-caudal axis of the mPFC. Rats 
found to have cannulae placements outside the anatomical boundaries of the mPFC or 
VTA were excluded from analysis. A total of three rats with misplaced VTA cannulae 
were excluded from the experimental analyses. 
2  
 
 
Figure 2.1 Histological analyses of intra-mPFC microinjection sites.  
(A) Microphotograph of a representative injector placement within the PLC division of 
the mPFC. (B) Schematic representation of select intra-PLC injector locations; ♦ = 500 
ng WIN 55, 212-2 versus 5 mg/kg morphine group, ◊ = 500 ng AM 251 versus 0.05 
mg/kg morphine group. 
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2.3.2 Intra-PLC CB1 receptor activation switches the motivational 
effects of morphine from rewarding to aversive 
We performed bilateral intra-PLC microinfusions of the CB1 agonist WIN 55,212-2 (50 
or 500ng/0.5μl), before either sub or supra-reward threshold morphine CPP conditioning. 
These doses of intra-cranial WIN 55,212-2 are pharmacologically specific and can be 
blocked by co-administration of selective CB1 antagonists (Laviolette and Grace, 2006; 
Tan et al., 2011). First, challenging the motivational effects of a sub-threshold 
conditioning dose of morphine (0.05 mg/kg, i.p.), two-way ANOVA revealed a 
significant interaction between group and treatment (F(2,43) = 38.6; p < 0.001) on times 
spent in either saline or morphine paired environments during CPP testing. Post hoc 
analysis revealed that whereas rats receiving a higher dose of WIN 55,212-2 
(500ng/0.5μl) demonstrated a significant aversion to morphine-paired environments (n = 
8, p < 0.01), this effect was absent in rats receiving a lower dose of WIN 55,212-2 
(50ng/0.5μl; n = 7), or vehicle (n = 7) with rats spending equal times in both 
environments (p > 0.05; Fig. 2.2A). Based upon this dose-dependent effect, we chose the 
highest behaviorally effective dose of 500ng/0.5μl of WIN 55,212-2 for subsequent 
behavioral experiments. In our next series of experiments, we microinfused WIN 55,212-
2 (500ng) and challenged a suprathreshold conditioning dose of morphine (5.0 mg/kg, 
i.p.). Two-way ANOVA revealed a significant interaction between group and treatment 
(F(1,31) = 673.7; p < 0.001). Post hoc analysis revealed a highly significant aversion to 
morphine-paired environments at testing in rats receiving intra-PLC WIN 55,212-2 (n = 
8, p < 0.01; Fig. 2.2B). Furthermore, comparing times spent in morphine-paired 
environments across groups, revealed that rats receiving intra-PLC WIN 55, 212-2 spent 
significantly less time in morphine-paired environments relative to vehicle controls (n = 
7; p < 0.01). Thus, whereas intra-PLC CB1 receptor activation produced no motivational 
effects in and of itself, activation of CB1 transmission potently and dose-dependently 
switched the motivational valence of both sub and supra-reward threshold doses of 
morphine into robust aversive behavioral responses. To control for any potential 
behavioral effects of intra-PLC WIN 55,212-2, we ran a subsequent control group (n = 8) 
in which rats received either the previously established effective dose of WIN 55,212-2 
(500 ng/0.5 μl) in one environment, or vehicle microinfusions in the control environment. 
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Statistical analysis revealed that intra-PLC WIN 55,212-2 produced no motivational 
effects, with rats demonstrating neither preference nor aversion for WIN 55,212-2-paired 
environments (t(7) = 2.1, p > 0.05; Fig. 2.2C). 
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Figure 2.2 Effects of intra-PLC CB1 receptor activation on morphine CPP 
conditioning. 
(A) Bilateral intra-PLC micro-infusions of the CB1 receptor agonist WIN 55,212-2 
(50 and 500ng/0.5μl), dose-dependently produced a morphine aversion against a sub-
reward threshold conditioning dose of morphine (0.05 mg/kg, i.p.). Both vehicle controls 
and rats receiving a lower dose of WIN 55,212-2 (50ng/0.5μl; n = 7) display no 
significant preference for either environment. Conversely, animals receiving the higher 
dose of WIN 55,212-2 (500ng/0.5μl; n = 8) display a significant aversion to morphine-
paired environments. (B) Bilateral intra-PLC microinfusions of WIN 55,212-2 
(500ng/0.5μl; n = 8) or vehicle (n = 7) versus a supra-reward threshold dose of morphine 
(5.0 mg/kg, i.p.) similarly switches the rewarding properties of morphine into aversion, 
with rats demonstrating robust CPA for morphine-paired environments. (C) In control 
rats receiving intra-PLC WIN 55,212-2 (500ng/0.5μl; n = 8) versus vehicle, no 
preference for either environment is observed. *p < 0.05; **p < 0.01, for this and all 
subsequent figures. 
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2.3.3 Intra-PLC CB1 receptor blockade potentiates the rewarding 
properties of morphine 
We next examined the potential effects of intra-PLC CB1 receptor blockade on the 
motivational behavioral effects of either sub or supra-reward threshold conditioning 
doses of morphine with the selective CB1 antagonist, AM251 (50 –500ng/0.5μl). First, 
challenging the behavioral effects of a sub-reward threshold conditioning dose of 
morphine (0.05 mg/kg, i.p.), we administered either 50 or 500 ng/0.5μl directly into the 
PLC. Two-way ANOVA demonstrated a significant interaction between group and 
treatment (F(2,43) = 76.2; p < 0.001) on times spent in either saline or morphine paired 
environments. Post hoc analysis revealed that animals receiving intra-PLC micro-
infusions of AM251 (500ng/0.5μl, n = 8, p < 0.001) spent significantly more time in 
morphine-paired environments (Fig. 2.3A). However, for the vehicle control group (n = 
8) and rats receiving a lower dose of AM 251 (50ng/0.5 μl, n =7), no CPP was observed. 
Furthermore, comparing times spent in morphine-paired environments across groups 
revealed that rats receiving intra-PLC AM251 (500 ng/0.5 μl) spent significantly greater 
times in morphine-paired environments, relative to controls (p < 0.01). Based upon this 
initial dose–response analysis, we chose the highest behaviorally effective dose of 
500ng/0.5μl of AM251 for subsequent behavioral experiments. We next examined the 
potential effects of intra-PLC AM251 (500ng/0.5μl) against a supra-reward threshold 
conditioning dose of morphine (5 mg/kg, i.p.). Two- way ANOVA demonstrated a 
significant interaction F(1,31) = 15.8; p = 0.0005) be- tween group and treatment, with 
rats receiving either intra-PLC vehicle or AM251 demonstrating significant CPP for 
morphine-paired environments (n = 8, p < 0.01; n = 8, p < 0.01 respectively; Fig. 2.3B). 
To control for any potential behavioral effects of intra-PLC AM251, we ran a subsequent 
control group (n = 8) in which rats received either the previously established effective 
dose of AM251 (500ng/0.5μl) in one environment, or vehicle microinfusions in the 
control environment. Statistical analysis revealed that intra-PLC AM251 produced no 
motivational effects, with rats demonstrating neither preference nor aversion for AM251-
paired environments (t(7) = 0.89, p > 0.05; Fig. 2.3C). Thus, whereas intra-PLC CB1 
receptor blockade produced no motivational effects in and of itself, blockade of CB1 
transmission potently and dose-dependently potentiated the rewarding properties of a 
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normally sub-reward threshold conditioning dose of morphine, while having no effect on 
the rewarding properties of a supra-reward threshold dose of morphine. 
In Figure 2.4, we present a summary of the behavioral conditioning effects of intra-PLC 
CB1 receptor blockade (AM 251) or activation (WIN 55,212-2) on the motivational 
properties of morphine, showing average difference scores (times in drug minus saline- 
paired environments), comparing sub-reward threshold morphine effects (Fig. 2.4A) or 
supra-reward threshold morphine effects (Fig. 2.4B). 
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Figure 2.3 Effects of intra-PLC CB1 receptor blockade on morphine CPP 
conditioning. 
(A) Bilateral intra-PLC microinfusions of the CB1 receptor antagonist, AM251 
(50ng/0.5μl; n = 8, or 500ng/0.5μl; n = 7) dose-dependently potentiated the rewarding 
effects of morphine relative to vehicle controls that displayed no significant preference for 
either environment. (B) Conversely, bilateral intra-PLC microinfusions of AM251 
(500ng/0.5μl) versus a supra-reward threshold dose of morphine (5.0 mg/kg, i.p) has no 
effect on morphine reward conditioning, with both drug (n = 8) and vehicle control (n = 8) 
groups demonstrating robust morphine environment CPP. (C) In control rats receiving 
intra-PLC AM251 (500ng/0.5μl; n = 8) versus vehicle, no preference for either 
environment is observed. 
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Figure 2.4 Behavioral effects of intra-PLC CB1 receptor activation or blockade on 
morphine place conditioning.  
(A) Summary of the bidirectional behavioral effects of intra-PLC AM-251 (50–
500ng/0.5μl) or WIN 55,212-2 (50–500ng/0.5μl) on sub-threshold morphine (0.05 
mg/kg, i.p.) reward or aversion effects, presented as difference scores (time in drug minus 
saline-paired environments). (B) Summary of the effects of intra-PLC AM 251 
(500ng/0.5μl) or WIN 55 212-2 (500ng/0. μl) on supra-reward threshold (5.0 mg/kg, i.p.) 
morphine. 
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2.3.4 CB1 receptor modulation of opiate reward learning is dopamine 
dependent  
Given our findings that intra-PLC CB1 receptor transmission modulates opiate reward 
and aversion signals (Figs. 2.2, 2.3), we next examined the potential functional 
interactions between intra-PLC CB1 receptor modulation and DAergic transmission. 
Accordingly, we challenged both the morphine reward-potentiating and aversion-
inducing effects of intra-PLC CB1 receptor modulation by pretreating rats with the 
broad-spectrum DA receptor antagonist (α-flupenthixol), using a systemic dose (0.8 
mg/kg, i.p.) which has been shown previously to block the rewarding properties of 
opiates in the opiate-dependent/withdrawn state (Laviolette et al., 2004). First, we 
challenged the ability of intra- PLC WIN 55, 212-2 (500 ng/0.5 ml) to induce morphine 
place aversions, with α-flu pretreatment (see Materials and Methods) versus supra-reward 
threshold conditioning dose of morphine (5 mg/kg, i.p.). Two-way ANOVA revealed a 
significant interaction between treatment and group (F(1,29) = 81.33; p < 0.001). Post 
hoc analysis revealed that rats treated with intra-PLC vehicle demonstrated a robust 
morphine CPP (n = 8; p < 0.01), whereas, consistent with our previous results (Fig. 2.2), 
rats treated with intra-PLC WIN 55,212-2 (n = 7) demonstrated a strong morphine 
environment aversion (p < 0.01; Fig. 2.5A). However, in rats pretreated with α-flu (n = 
7), the ability of intra-PLC CB1 receptor activation to induce a morphine place aversion 
was completely blocked, with rats showing no preference or aversion for either 
environment at testing (p < 0.05; Fig. 2.5A). 
Next, we challenged the ability of intra-PLC AM251 (500 ng/ 0.5 ml) to potentiate the 
rewarding effects of a sub-reward conditioning dose of morphine (0.05 mg/kg, i.p.), with 
α-flu pretreatment. Two-way ANOVA revealed a significant interaction between 
treatment and group (F(1,27) = 257.25; p < 0.001). Post hoc analysis revealed that rats 
treated with intra-PLC vehicle demonstrated no preference for environments paired with 
sub-reward threshold morphine (n = 8; p > .05). In contrast, consistent with our previous 
results (Fig. 2.2), rats treated with intra-PLC AM251 (n = 7) demonstrated a strong 
morphine place preference ( p < 0.01; Fig. 2.5B). However, in rats pretreated with α-flu 
(n = 8), the ability of intra-PLC CB1 receptor blockade to potentiate the rewarding 
38 
 
properties of morphine were completely blocked, with rats showing neither preference 
nor aversion for either environment at testing (p < 0.05; Fig. 2.5B). 
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Figure 2.5 Effects of DA receptor blockade on intra-PLC mediated modulation of 
opiate motivational properties. 
(A) Rats treated with intra-PLC vehicle demonstrate robust CPP for environments paired 
with supra-reward threshold morphine (n = 8). Relative to vehicle pretreated controls (n = 
8), pretreatment with the broad-spectrum DA receptor antagonist α-flu (0.8 mg/kg, i.p.) 
blocked the ability of intra-PLC WIN 55,212-2 (500ng/0.5μl; n = 7) to induce a 
behavioral morphine aversion to a supra-reward threshold conditioning dose of morphine 
(5.0 mg/kg, i.p.). (B) Rats treated with intra-PLC vehicle demonstrated no preference for 
environments paired with sub-reward threshold morphine (n = 8). In contrast, rats treated 
with intra-PLC AM251 (n = 7) demonstrated a strong morphine CPP (p < 0.01; B). 
However, in rats pretreated with α-flu (n = 8), the ability of intra-PLC CB1 receptor 
blockade to potentiate the rewarding properties of morphine is blocked. 
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2.3.5 Intra-PLC CB1-mediated morphine aversions are mediated through 
κ-opiate receptor transmission in the VTA 
Given the well established role of κ-opiate receptor transmission within the VTA in the 
mediation of opiate-related aversion (Margolis et al., 2003), we next tested whether the 
ability of intra-PLC CB1 activation to induce morphine-related place aversion was 
dependent upon a KOR substrate directly within the VTA. Thus, we challenged the 
aversion-inducing effects of intra-PLC WIN 55,212-2 (500ng/0.5μl) with the highly 
selective KOR antagonist nor-binaltorphimine dehydrochloride (nor-BNI) by 
microinfusing nor-BNI into the VTA (50 –500ng/0.5μl) before intra-PLC CB1 receptor 
activation (see Materials and Methods), using a supra-reward threshold conditioning dose 
of morphine (5 mg/kg, i.p.). Two-way ANOVA revealed a significant interaction 
(F(1,27) = 41; p < 0.001) between group and treatment. Post hoc analysis revealed that 
for rats receiving a lower dose of intra- VTA nor-BNI (50ng/0.5μl; n = 8), a morphine 
environment aversion was present (p < 0.05), similar, although slightly attenuated, 
relative to controls receiving only intra-PLC WIN 55,212-2 (n = 8; p < 0.01; Fig. 2.6A). 
In contrast, for rats receiving a higher dose of intra-VTA nor-BNI, morphine 
environment aversions were completely blocked, and rats displayed a robust morphine 
CPP (n = 6, p < 0.01). Thus, blockade of KOR signaling in the VTA dose-dependently 
reversed the ability of intra-PLC WIN 55, 212-2 to induce morphine environment 
aversions, and revealed the rewarding behavioral effects of a supra-reward threshold 
conditioning dose of morphine (Fig. 2.6A). To determine the specificity of the intra-VTA 
KOR mediated effect, we ran an additional control group receiving intra-PLC WIN 
55,212-2 with intra-VTA cyprodime hydrochloride, a highly competitive MOR 
antagonist (n = 6). This group displayed a robust morphine-environment aversion; 
consistent with previous results (Fig. 2.2) demonstrating that intra-VTA MOR 
transmission is not involved in the aversion-inducing effects of intra-PLC CB1 receptor 
activation (t(6) = 14.9; p < 0.01; Fig. 2.6A, right). 
To control for any potential motivational effects of intra-VTA nor-BNI alone, an 
additional control group (n = 8) received bilateral intra-VTA cannulations and received 
the highest behaviorally effective dose of intra-VTA nor-BNI (500ng/0.5μl) in one 
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conditioning environment, and intra-VTA vehicle in the alternate environment. Analysis 
of CPP behavior revealed that intra-VTA nor-BNI produced no motivational effects in 
and of itself as rats did not demonstrate any significant difference in times spent in either 
conditioning environment (Fig. 2.6A, right; t(7) = 1.1814, p > 0.05). 
 
43 
 
 
 
 
 
 
44 
 
Figure 2.6 Effects of intra-VTA κ or μ-opiate receptor blockade on CB1 receptor 
mediated modulation of opiate reward and aversion behaviors. 
(A) Relative to rats receiving intra-PLC WIN 55,212-2 (500ng/0.5 ml) versus supra-
reward threshold morphine (n = 8), intra-PLC administration of WIN 55,212-2 
(500ng/0.5μl) following intra-VTA administration of the KOR antagonist nor-BNI [50 (n 
= 8) or 500 (n = 6) ng/0.5μl] dose-dependently blocks the ability of intra-PLC CB1 
activation to switch morphine reward signaling into aversion. However, intra-VTA 
administration of a MOR antagonist, cyprodime (500ng/0.5μl; n = 6) fails to reverse the 
effects of intra-PLC CB1 activation. Intra-VTA administration of the highest effective 
dose of nor-BNI (500 ng/0.5 μl) does not produce any behavioral motivational effects in 
and of itself (n = 8; right). (B) Intra-PLC administration of AM251 (500ng/0.5μl) 
following intra-VTA administration of the MOR antagonist cyprodime [50 (n = 7) or 500 
(n = 7) ng/0.5μl] dose-dependently blocks the ability of intra-PLC CB1 receptor blockade 
to potentiate sub-reward threshold morphine effects, relative to intra-PLC AM251 alone 
(n = 8). In contrast, intra-VTA administration of the KOR antagonist, nor-BNI 
(500ng/0.5μl; n = 6) fails to reverse the effects of intra-PLC CB1 blockade. Intra-VTA 
administration of the highest effective dose of cyprodime (500ng/0.5μl) does not produce 
any behavioral motivational effects in and of itself (n = 8; right). 
 
 
 
 
 
 
 
 
 
 
 
45 
 
2.3.6 Intra-PLC CB1-mediated morphine reward potentiation is 
mediated through μ-opiate receptor transmission in the VTA 
We next tested whether the ability of intra-PLC CB1 blockade to potentiate the rewarding 
effects of morphine were dependent upon a MOR substrate directly within the VTA. 
Thus, we challenged the reward-potentiating effects of intra-PLC AM251 (500ng/0.5μl) 
with the highly selective MOR antagonist cyprodime hydrochloride, by directly 
microinfusing cyprodime into the VTA (50–500ng/0.5μl) before intra-PLC CB1 receptor 
blockade (see Materials and Methods), using a sub-reward conditioning dose of morphine 
(0.05mg/kg; i.p.). Two-way ANOVA revealed a significant interaction (F(1,27) = 72.7; p 
< 0.001) between group and treatment. Post hoc analysis revealed that for rats receiving a 
lower dose of cyprodime (50ng/0.5μl), intra-PLC AM251 was able to potentiate the 
rewarding properties of sub-reward thresh- old morphine, with these rats demonstrating a 
significant morphine CPP (n = 7, p < 0.05; Fig. 2.6B). However, in rats receiving a higher 
dose of intra-VTA cyprodime (500ng/0.5μl), the morphine reward potentiating effects of 
intra-PLC AM251 were completely blocked, with rats showing no preference for 
morphine-paired environments (n = 7; p > 0.05; Fig. 2.6B). Thus, intra-VTA cyprodime 
dose-dependently reverses the behavioral effects of intra-PLC CB1 receptor blockade on 
morphine reward processing. To determine the specificity of the intra-VTA MOR- 
mediated effect, we ran an additional control group (n = 6) receiving intra-PLC AM251 
(500 ng/0.5μl) with our previously established effective dose of intra-VTA nor-BNI 
(500ng/0.5μl). These rats dis- played a potentiated morphine reward behavioral response 
(t(5) = 8.74; p < 0.01), consistent with previous results (Fig. 2.3), demonstrating that 
intra-VTA KOR transmission is not involved in the reward potentiating effects of intra-
PLC CB1 receptor blockade. To control for any potential motivational effects of intra-
VTA cyprodime alone, an additional control group (n = 8) received bilateral intra-VTA 
cannulations and received the highest behaviorally effective dose of intra-VTA 
cyprodime (500ng/0.5μl) in one conditioning environment, and intra-VTA vehicle in the 
alternate environment. Analysis of CPP behavior revealed that intra-VTA nor-BNI 
produced no motivational effects in and of itself as rats did not demonstrate any 
significant difference in times spent in either conditioning environment (Fig. 2.6B, right; 
t(7) = 0.7281, p > 0.05). Histological analysis of intra-VTA microinfusion locations 
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revealed injection sites to be within the anatomical boundaries of the VTA as defined by 
Paxinos and Watson (2006). In Figure 2.7A, we present a micro-photograph showing a 
typical bilateral intra-VTA cannulae placement. In Figure 2.7B, we present a schematic 
summary of intra-VTA microinjection locations. Post experimental histological analysis 
revealed that effective intra-VTA doses of nor-BNI (500ng/0.5μl) were predominantly 
localized to the anterior VTA (Fig. 2.7C). Post experimental histological analysis 
revealed that effective intra-VTA doses of cyprodime (500ng/0.5μl) were predominantly 
localized to the posterior VTA (Fig. 2.7C). 
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Figure 2.7 Histological analyses of intra-VTA microinfusion locations. 
(A) Microphotograph showing representative bilateral intra-VTA infusion locations. (B) 
Schematic summary of intra-VTA microinjector locations;  = intra-VTA nor-BNI 
(500ng/0.5μl); � = intra-VTA cyprodime (500ng/0.5μl). (C) Schematic summary 
showing relative intra-VTA cannulae placement locations relative to behavioral CPP 
index score (total time in saline environment + total time in morphine environment/total 
time in morphine environment; de Jaeger et al., 2013) for rats receiving the behaviorally 
effective doses of either intra-VTA cyprodime or nor-BNI. 
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2.4 DISCUSSION 
We report that CB1 transmission within the PLC division of the mPFC, bi-directionally 
modulates the motivational behavioral effects of systemic opiates. Although activation of 
CB1 transmission switched a normally rewarding behavioral effect of morphine into 
aversion, blockade of CB1 transmission potentiated the rewarding properties of normally 
sub- reward threshold conditioning doses of morphine. This CB1-mediated switching 
mechanism was functionally dissociable, DA dependent, and mediated through either a 
MOR-dependent reward substrate, or a KOR-dependent aversion signaling substrate, 
directly within the VTA. 
2.4.1 Bidirectional control of opiate reward and aversion signals through 
CB1 receptor transmission in prelimbic cortex 
Considerable evidence indicates functional interactions between opiate, cannabinoid, and 
DAergic transmission during the processing of motivationally salient information (Cheer 
et al., 2004; Sperlagh et al., 2009; Akirav and Fattore, 2011). Specifically, within the 
mPFC-VTA circuitry, CB1 receptor transmission modulates downstream DAergic 
activity within the VTA. In terms of functional interactions between the mPFC and VTA, 
the mPFC sends descending projections to neuronal subpopulations within the VTA, 
including both DAergic and non-DAergic neurons (Carr and Sesack, 2000a,b; Sesack and 
Carr, 2002). Interestingly, CB1 agonists have been reported to increase the spontaneous 
activity of mPFC neuronal populations and attenuate the inhibitory effects of VTA 
DAergic stimulation on mPFC neuronal activity, suggesting that systemic cannabinoid 
activation may remove tonic inhibitory influences of VTA DAergic inputs to the mPFC 
on cortical neuronal subpopulations (Pistis et al., 2001). 
In the context of fear-related learning and memory, considerable evidence implicates a 
role for intra-mPFC CB1 transmission. Thus, activation of CB1 transmission in the 
mPFC potentiates normally sub-threshold fear-memory formation behaviorally and 
associative neuronal conditioning (Laviolette and Grace, 2006). Cannabinoid 
transmission within the BLA also modulates fear memory processing via modulatory 
inputs to PLC neurons (Tan et al., 2010). In terms of reward-related learning and 
memory, CB1 transmission has been shown to modulate the rewarding properties of 
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opiates, via interactions with mesolimbic circuits. For example, CB1 receptor agonists 
such as WIN 55,212-2 have been shown to directly excite DA neuron activity within the 
VTA (French et al., 199 ) and potentiate the reward salience of opioids (Caille  and 
Parsons, 2006). Nevertheless, most previous studies have used systemic administration of 
cannabinoid agents and little is known related to how direct CB1 signaling within 
specific cortical regions, such as the PLC, may modulate reward-related signals. 
Given previous evidence showing that CB1 agonists can increase subcortical DAegic 
transmission (French et al., 1997; Pistis et al., 2001, 2002; Cheer et al., 2004), our initial 
hypothesis was that CB1 activation would potentiate the reward salience of opiates by 
directly activating a DA-dependent reward pathway in the VTA. Instead, we observed the 
opposite effect, with CB1 receptor blockade potentiating opiate-reward salience and CB1 
activation instead inducing aversive opiate-related behavioral effects. Nevertheless, given 
the complexity of CB1-mediated control of neuronal network signaling within cortical 
regions, several functional explanations are possible. For example, in addition to the well 
established role of CB1 receptor transmission in inhibiting feed forward, GABAergic 
inhibitory inputs to principal output neurons (Katona et al., 2001; Freund et al., 2003), 
CB1 receptors also control presynaptic GLUTergic release in various neural regions, 
including the hippocampus, BLA, and sensory cortical areas (Domenici et al., 2006). One 
important source of GLUTergic inputs to the mPFC arises from the BLA. Indeed, CB1 
transmission modulates LTP along the BLA-mPFC pathway (Tan et al., 2010, 2011) and 
is necessary for the effects of intra-PLC CB1 transmission on potentiation of fear-related 
memory and GLUTergic modulation of opiate reward memory formation (Laviolette and 
Grace, 2006; Bishop et al., 2011). Thus, one possibility is that intra-PLC CB1 activation 
may inhibit excitatory inputs to PLC output neuron populations, in turn leading to 
dysregulated or attenuated PLC signaling to downstream DAergic substrates in the VTA. 
In vitro studies have demonstrated bidirectional effects of either CB1 activation or 
blockade on GLUTergic synaptic strength within the mPFC. Thus, CB1 activation 
suppresses EPSCs, whereas CB1 blockade increases GLUTergic EPSCs recorded in slice 
(Auclair et al., 2000). Furthermore, DAergic transmission has been shown to modulate 
synaptic plasticity within the mPFC (Chiu et al., 2010). 
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Given the bidirectional behavioral effects observed in the present study, an alternative 
possibility is that CB1 blockade may in- crease GLUTergic synaptic strength leading to 
increased PLC output neuron activity to downstream DAergic substrates in the VTA, 
with CB1 receptor activation producing the opposite functional effect. Although future 
studies are required to investigate these possibilities, this model could account for 
AM251-induced activation of down- stream DA signaling and subsequent potentiation of 
opiate reward salience (by increasing GLUTergic output from the PLC) and by extension, 
WIN 55,212-2- induced inhibition of GLUTergic output from the PLC and a hypothetical 
inhibition of downstream DAergic transmission. However, such a mechanism cannot 
account for the observed switch to a robust, DA-dependent behavioral aversion signal. 
Furthermore, the rewarding effects of opiates can be mediated in- dependently of DA in 
the previously opiate-naive state (Laviolette et al., 2004). 
2.4.2 Cannabinoid modulation of opiate reward and aversion signals is 
mediated through separate μ- versus κ-opiate receptor substrates 
  Opiates, such as morphine, possess rewarding and aversive stimulus properties. 
Considerable evidence demonstrates dissociable mechanisms within the VTA for the 
mediation of MOR versus KOR-mediated reinforcing versus aversive behavioral effects. 
Thus, whereas MOR activation is linked to DA neuron activation via indirect inhibition 
of inhibitory GABAergic VTA neuronal populations (Johnson and North, 1992), KOR- 
dependent aversion signals have been linked to direct inhibitory effects on VTA DAergic 
substrates (Margolis et al., 2003, 2006). Morphine, although showing preferential affinity 
for the μ-type opiate receptor, also shows affinity for δ and κ receptor subtypes (Yamada 
et al., 2006), suggesting that multiple opiate receptor pathways may be capable of 
mediating morphine’s behavioral and motivational properties. The aversive effects of 
systemic morphine have previously been shown to depend on peripheral κ-receptor 
substrates (Bechara and van der Kooy, 1987; Bechara et al., 1987). The present results 
demonstrate that central blockade of κ receptors directly within the VTA are capable also 
of blocking the aversive effects of systemic morphine. Although beyond the scope of the 
current studies, an interesting question would be whether the ability of intra-PLC 
cannabinoid activation to induce morphine-aversion effects may be similarly blocked by 
systemic blockade of κ receptors, extrinsic to centrally localized κ-receptor substrates 
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within the VTA. 
In the present study, we observed that both the reward or aversion-related effects of CB1 
receptor modulation were DA-dependent. Previous evidence has suggested that KOR-
sensitive DA neurons within the VTA preferentially send recurrent projections back to 
the mPFC. Although the current study used a systemically administered, broad-spectrum 
DA receptor antagonist, one possibility is that the aversive effects of intra-PLC CB1 
activation, mediated through a KOR-sensitive substrate in the VTA, involves a recurrent 
pathway from the PLC to select DA neurons in the VTA, which then project back to PLC 
neuronal substrates. Activation of VTA KORs associated with DAergic neuronal sub- 
populations selectively reduces DA release in the mPFC, but not in the NAc, further 
suggesting that aversive opiate-related behavioral effects may be mediated through 
recurrent mPFC-VTA circuitry (Margolis et al., 2006). 
Alternatively, the mPFC sends strong GLUTergic projections to the VTA, which are 
known to synapse upon both DAergic and non-DAergic (presumably GABAergic) 
neuronal subpopulations and again, these inputs appear to selectively target recurrent 
DAergic projections back up to the mPFC (Sesack and Carr, 2002). Given the present 
findings wherein the CB1-mediated switch from opiate reward to aversion was dependent 
upon both DAergic and KOR-dependent transmission, intra-PLC CB1 activation may 
selectively activate efferents to the VTA, which act directly upon KOR substrates 
associated with VTA DAergic neuronal populations, leading to dysregulation and/or 
attenuation of DA signaling back up to the mPFC. In contrast, the DA- dependent, reward 
potentiating effects of intra-PLC CB1 receptor blockade were mediated through MOR, 
but independent of KOR signaling within the VTA. This would suggest that inhibition of 
CB1 transmission within the PLC may indirectly activate DA-dependent reward salience 
signaling in the VTA via MOR substrates, likely associated with non-DA, GABAergic 
neuronal subpopulations in the VTA, as suggested by previous reports (Gysling and 
Wang, 1983; Johnson and North, 1992). Interestingly, MOR-associated DAergic neurons 
within the VTA have been shown to preferentially project to the BLA (Ford et al., 2006). 
Although future studies are required to examine these issues, one possibility is that opiate 
reward signals are amplified through a PLC-VTA-BLA circuit, via MOR-mediated 
53 
 
activation of VTA3BLA DA projections. Indeed, we have reported previously that direct 
activation of DA D1 receptor transmission within the BLA can strongly potentiate 
normally sub-reward thresh- old morphine conditioning signals (Lintas et al., 2012), 
suggesting a putative mechanism whereby increased DA input to the BLA may increase 
opiate-related reward salience, as observed in the present studies. In summary, the 
present findings add new insights into the role of prefrontal cortical cannabinoid 
transmission on the modulation of motivationally salient, reward-related memory 
processing. Furthermore, the present findings suggest that disturbances in CB1 
transmission within mPFC circuits may underlie subcortical DAergic dysregulation 
linked to neuropsychiatric disorders, such as addiction and schizophrenia. 
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Chapter 3 
 
 
3 Bi-directional cannabinoid signaling in the basolateral 
amygdala controls rewarding and aversive emotional 
processing via functional regulation of nucleus accumbens 1 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1
 This chapter has been adapted from the submitted journal article: Ahmad, T., Sun, N., Lyons, D., and 
Laviolette, S.R. (2016). Bi-directional cannabinoid signaling in the basolateral amygdala controls 
rewarding and aversive emotional processing via functional regulation of the nucleus accumbens. Addiction 
Biology (Accepted March 2016, In print) 
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3.1 INTRODUCTION 
Drugs that modulate the brains cannabinoid system such as marijuana, can powerfully 
modulate both positive and negative affective states (Hart et al., 2002; Metrik et al., 
2011). The cannabinoid CB1 receptor (CB1R) is localized to neural regions responsible 
for emotional processing, including the basolateral amygdala (BLA) and mesolimbic 
pathway (Katona et al., 2001).  Projections from the BLA to the nucleus accumbens 
(NAc), not only modulate opiate-reward salience and memory formation (Lintas et al., 
2012), but also the activity of NAc neuronal subpopulations via glutamatergic 
(GLUTergic) projections and dopamine (DA)-dependent receptor transmission (Floresco 
et al., 2001). Modulation of intra-BLA CB1R transmission strongly modulates rewarding 
or aversive associative memory formation and associated plasticity mechanisms (Azad et 
al., 2004; Ramikie & Patel, 2012; Tan et al., 2011). In addition, CB1R transmission 
modulates the BLANAc pathway. For example, administration of CB1R agonists 
suppresses excitatory BLA control of NAc neuronal activity and inhibits spontaneous 
activity levels of BLA projection neurons (Pistis et al., 2002, 2004), demonstrating an 
important role for CB1R modulation of the BLANAc circuit. 
The NAc serves as a limbic-motor interface where motivationally salient information is 
converted into goal directed behaviors (Mogenson, Swanson, & Wu, 1983). 
Approximately 95% of the neuronal population within the NAc is comprised of 
GABAergic, medium spiny neurons (MSNs) with the remainder consisting of 
GABAergic or cholinergic fast-spiking interneurons (FSIs). Considerable evidence 
demonstrates that encoding of aversive vs. rewarding information is linked to differential 
FSI vs. MSN neuronal activity patterns (Carlezon and Thomas, 2009; Sun and Laviolette, 
2015). Nevertheless, the potential effects of CB1R modulation on intra-NAc neuronal 
encoding of opiate-related motivational information are not currently understood. 
In the present study we examined the role of intra-BLA CB1R transmission in the 
processing of opiate-related motivational behaviors. We report that intra-BLA CB1R 
transmission bi-directionally controls opiate-related motivational valence; while blockade 
of BLA CB1R dramatically potentiates the reward salience of normally sub-threshold 
opiate conditioning doses, activation of CB1R switches the motivational valence of 
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opiates from rewarding to aversive through DA-dependent mechanisms and were 
functionally mediated through BLANAc GLUTergic projections to the shell region of 
the NAc (NASh). Furthermore, intra-BLA CB1R transmission bi-directionally controls 
MSN vs. FSI mediated neuronal correlates of opiate-mediated reward or aversion 
behaviors both during opiate-related reward conditioning and recall of rewarding or 
aversive associative memories.  
3.2 MATERIALS AND METHODS 
3.2.1 Animals and Surgery 
All experimental procedures were approved by the Canadian Council on Animal Care. 
Adult male Sprague Dawley rats (350-400 gm; Charles River, Canada) were anesthetized 
with a ketamine (80mg/ml)-xylazine (6mg/kg) mixture (i.p), and placed in a stereotaxic 
device. For microinfusions into the BLA, NASh or NACore, two guide cannulae (22 
gauge; PlasticsOne) were implanted bilaterally using the following stereotaxic 
coordinates (Paxinos and Watson, 2005): for the BLA (0° angle), from bregma: antero-
posterior (AP)-2.6mm, lateral (L)±5.0mm, from the dural surface, ventral (V)-7.2mm; for 
NAcore (8° angle), from bregma AP+1.8mm, L ±2.7mm, from dural surface, V -7.4mm; 
for NA shell (12° angle), from bregma AP +1.8mm, L ±2.6mm, from dural surface, V -
7.4mm. For in vivo neuronal recordings, an eight channel micro-wire array (Tucker-
Davis) was implanted unilaterally in the NA shell with the following coordinates 
(Paxinos, 2005): 0° angle, (AP)+2.2mm, lateral (L)±1.2mm, from the dural surface, 
ventral (V)-7.0mm.  
3.2.2 Drug Treatments 
The CB1R agonist (WIN 55,212-2, Tocris) and antagonist (AM 251, Tocris) were 
dissolved in dimethyl sulfoxide (DMSO) and diluted in physiological saline (pH adjusted 
to 7.4). The dose-ranges of AM 251 and WIN 55 (50-500ng/0.5l) were based upon 
previously published reports demonstrating that intra-cranial infusions within this range 
are pharmacologically specific and behaviorally effective (Laviolette and Grace, 2006). 
The NMDA receptor antagonist (DL-AP5, Tocris) and DA receptor antagonist, -
flupenthixol (-flu; Tocris) were dissolved in physiological saline. Bilateral micro-
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infusions (0.5 l volume) were performed over 1 min via a 1 μl Hamilton syringe. 
Injectors were left in place for an additional 1 min to ensure adequate diffusion from the 
injector. Morphine sulphate (Macfarland-Smith) was dissolved in physiological saline. 
Two conditioning doses of morphine were used: a supra-reward threshold dose of 5mg/kg 
which produces robust morphine CPP, or a sub-reward threshold conditioning dose of 
0.05 mg/kg, which alone produces no significant behavioral CPP effects (Bishop, 
Lauzon, Bechard, Gholizadeh, & Laviolette, 2011; Lintas et al., 2011). For experiments 
using -flu, we used a previously characterized dose (0.8 mg/kg; i.p.) administered 2.5 
hours prior to conditioning. This dose and administration time produces no motivational 
effects in and of itself, as previously reported (Laviolette and van der Kooy, 2003). 
3.2.3 Place Conditioning 
Conditioning experiments used an unbiased conditioned place preference (CPP) 
paradigm as previously described (De Jaeger et al., 2013; Lauzon, Bechard, Ahmad, & 
Laviolette, 2013). One environment was white with a wire mesh floor covered with 
woodchips, and the other environment was black, with a smooth Plexiglass floor wiped 
down with 2% acetic acid. Rats were randomly assigned to vehicle or morphine-paired 
environments and received 4 saline/environment and 4 morphine/environment pairings 
over the 8-day conditioning phase. Rats received intra-BLA drug microinfusions 
followed by an i.p injection of saline or morphine, before being placed in conditioning 
environments. For intra-NAc experiments, rats received bilateral microinfusions of AP5 
(1 g/0.5 l) in either the NACo or NASh immediately prior to conditioning. Following 
conditioning, rats received a CPP recall test in a drug free state. During CPP testing, the 
rat is placed on a grey zone, separating the two conditioning environments, and allowed 
to move freely between the two environments for a period of 10 min. Times spent in each 
box are digitally recorded (digital timers) for subsequent analysis. 
3.2.4 In-vivo Electrophysiology Recordings 
The in vivo micro-wire array recordings followed the procedure previously described 
(Sun & Laviolette, 2012, 2014). Briefly, 8-channel micro-wire arrays (model MW8, 
Tucker-Davis) were implanted unilaterally into the NASh, using the above described 
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stereotaxic procedures.  The dimension of the array was 200 μm in length by 500μm in 
width, consisting of two rows of four micro-wires, separated by 50μm. The array was 
connected to an RA-16PA pre-amplifier and then sent to a Pentusa Base Station (model 
RX5, Tucker-Davis). Neuronal spike signals were sampled at 25 kHz/channel with filter 
settings of 100Hz (high-pass) and 5kHz (low-pass), and were then sent to a window 
discriminator/amplifier and an audio monitor. The neuronal activity from the NASh was 
recorded (Open Ex, Tucker- Davis), and stored in a data tank for offline analysis, where 
spikes were sorted using K-means analysis (OpenSort, TDT). To ensure rats had no pre-
existing differences in neuronal responses to conditioning environments, baseline 
recordings were performed for a period of 10 min for each rat, counterbalanced for the 
two environments, over 2 days prior to conditioning. Next, during the acquisition phase 
prior to each conditioning session, baseline recordings (10 min) were performed in the 
home cage.  Baseline recordings were then averaged out for subsequent comparison to 
recordings performed during conditioning trials. Off-line analyses of NASh neuronal 
activity parameters involved manually sorting isolated waveforms within each channel to 
either fast spiking interneurons (FSI), or presumptive medium spiny neurons (MSN). The 
classification parameters of FSI vs. MSN units were determined through offline spike 
waveform and firing frequency sorting as described previously (Sun and Laviolette, 
2015) and based upon previously reported electrophysiological criteria for identification 
of FSI vs MSN NAc neuronal units recording in vivo (Berke, Okatan, Skurski, & 
Eichenbaum, 2004; Berke, 2008; Morra, Glick, & Cheer, 2010). Putative MSN vs. FSI 
neuronal sub-populations were sorted offline using K-means cluster analysis which 
separates isolated units based upon completion of waveform sorting, single units were 
further characterized as FSI or MSN units using inter-spike interval (ISI) histograms 
constructed for each isolated neuronal unit. Sample rastergrams and ISI histograms were 
prepared using NeuroExplorer.  Neurons were manually sorted based on waveform shape 
and Interval histograms (see Fig.3.3). A subpopulation of neurons met previously 
established criteria for FSIs (Berke et al., 2004). Neurons with slow waveform shapes 
(peak widths 120 us; valley widths 265 us) and low firing rates (<5 Hz) were presumed to 
be medium spiny neurons (MSNs) (Morra et al., 2010). 
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3.2.5 Histology 
At the completion of experiments, rats were anesthetized with an overdose of Euthanyl 
(Sodium Pentobarbitol, 240 mg/kg; i.p.) and perfused with isotonic saline followed by 
10% formalin. Brains were extracted, sliced at 40 μm, and stained with Cresyl Violet to 
allow for histological analysis of injection sites. Rats with misplaced guide cannulae were 
excluded from analyses. 
3.2.6 Data Analysis 
Data were analyzed with either One or Two-way analysis of variance (ANOVA) or 
student’s t-tests where appropriate. Post hoc analyses were performed with Newman-
Keuls or Fisher’s least significant difference tests, where appropriate. 
3.3 RESULTS 
3.3.1 Intra-BLA CB1R blockade amplifies the motivational salience of 
sub-reward threshold morphine 
We first examined the effects of intra-BLA CB1R blockade on morphine-related reward 
processing by challenging the effects of a sub-reward threshold conditioning dose of 
morphine (0.05 mg/kg; i.p.) with intra-BLA microinfusions of the CB1R antagonist AM 
251 (50-500ng/0.5μl; Fig. 3.1A). Two-way ANOVA revealed a significant group x 
treatment interaction (F(2,41) = 31.5; p<0.0001) on times spent in morphine vs. vehicle-
paired environments. Post hoc analyses revealed that whereas rats receiving a dose of 
500ng/0.5μl  AM251 spent significantly more time in morphine-paired environments 
(n=7, p<0.01), vehicle controls (n=7) or rats receiving a lower dose of AM 251 (50ng/0.5 
p’s>0.05).  
Functional BLANAc projections have been reported to modulate mesolimbic DA 
release within the NAc and to control NAc neuronal activation via DA receptor 
transmission (Floresco et al., 2001; Jones et al., 2010). Accordingly, to determine if our 
observed effects might depend upon a DAergic transmission mechanism, an additional 
group of rats (n=7) were pre-treated with the broad- -
flu, 0.8 mg/kg, i.p., see methods) prior to intra-BLA CB1R blockade and sub-threshold 
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morphine conditioning. Analysis of CPP scores revealed that DA antagonist pre-
treatment blocked the ability of intra-BLA AM 251 to potentiate morphine reward 
salience (t6 = 1.03, p>0.05; Fig. 3.1A). Next, to control for possible motivational effects 
of AM 251 in and of itself, a separate control group received intra-BLA vehicle in one 
environment vs. the effective dose of AM 251 (500ng) in the alternate environment 
(n=8). Rats showed neither aversion nor preference for AM 251 paired environments (t7 
=1.62, p>0.05), indicating that AM 251 produced no motivational effects in and of itself 
(Fig. 3.1A far right). Based upon this initial AM 251 dose-response curve, a dose of 
500ng/0.5μl was used for all subsequent behavioral experiments.   
Next, challenging the effects of the supra-threshold dose of morphine, two-way ANOVA 
revealed a significant main effect of treatment on times spent in vehicle vs. morphine-
paired environments (F(1,29) = 56.2; p<.0001). Post hoc analyses revealed that both 
vehicle controls (n=7) and rats receiving intra-BLA AM 251 (n=8) displayed significant 
morphine CPP (p’s<.01; Fig. 3.1B). Post hoc analyses revealed no significant differences 
in times spent in environments paired with supra-reward threshold morphine (p’s >.05).  
Thus, whereas intra-BLA CB1R blockade potentiated the reward salience of sub-
threshold conditioning doses of morphine through a DA-dependent mechanism, this same 
treatment had no effect on supra-threshold morphine reward conditioning. 
3.3.2 Intra-BLA CB1R activation switches opiate motivational valence 
from rewarding to aversive 
We next examined the effects of bilateral intra-BLA CB1R activation with WIN 55 (50-
500 ng/0.5μl) on morphine CPP behaviors examining both sub (0.05 mg/kg; i.p.) or 
supra-reward threshold (5.0 mg/kg; i.p.) doses of morphine (see methods). First, 
examining the effects of intra-BLA WIN 55 on sub-threshold morphine CPP (Fig. 3.1C), 
two-way ANOVA showed a significant interaction between group and treatment (F(2,41) = 
20.97; p< .0001). Post hoc analysis revealed that animals receiving the higher dose of 
WIN 55 (500 ng) showed a significant aversion to the morphine-paired environment 
(CPA) (n=7, p<.01), whereas rats receiving vehicle (n=7) or a lower dose of WIN 55 (50 
ng; n=7) showed neither preference nor aversion for either environment (p’s>.05; Fig. 
3.1C).  
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To determine if the aversion-inducing effects of intra-BLA CB1R activation on morphine 
conditioning depended upon a DAergic transmission mechanism, an additional group of 
rats (n=8) were pre-treated with -flu (0.8 mg/kg; i.p.) prior to intra-BLA CB1R 
activation and sub-threshold morphine conditioning. Analysis of CPP scores revealed that 
-flu pre-treatment blocked the intra-BLA CB1R activation induced aversion, with rats 
demonstrating neither CPP nor CPA for either environment (t7 = 0.92, p>0.05; Fig. 
3.1C). To control for possible motivational effects of intra-BLA WIN-55 (500ng) in and 
of itself, a separate control group received intra-BLA vehicle in one environment vs. 
WIN 55 in the alternate environment (n=8). Rats showed neither CPP nor CPA for WIN 
55 paired environments (t7 =1.05, p=.33), indicating that intra-BLA CB1R activation 
produced no motivational effects in and of itself (Fig. 3.1C far right). Based on this initial 
WIN 55 dose-response curve, for all subsequent experiments, we administered the 
highest behaviorally effective dose of WIN 55 (500ng/0.5μl) to challenge the effects of 
morphine.  
Next, we challenged the effects of intra-BLA CB1R activation on a supra-reward dose of 
morphine (5.0 mg/kg; i.p.). Two-way ANOVA revealed a significant main effect of 
treatment on times spent in morphine vs. vehicle-paired environments (F(1,31)= 458.91; 
p<.0001). Post hoc analysis revealed a significant morphine CPA in rats receiving intra-
BLA WIN 55 (n=8, p<.01) whereas intra-BLA vehicle controls demonstrated a robust 
morphine-environment CPP (n= 8, p<.01; Fig. 3.1D). In Figures 3.1E,F, we summarize 
CPP results showing mean ‘difference scores’ comparing the behavioural effects of 
CB1R activation/blockade on sub (3.1E) vs. supra-reward threshold (3.1F) conditioning 
effects on morphine preference or aversion behaviors measured in the CPP test. Thus, 
while intra-BLA CB1R blockade strongly potentiated the reward salience of normally 
sub-reward conditioning doses of morphine, intra-BLA CB1R activation, produced the 
opposite effect, switching a normally rewarding behavioural effect of morphine into a 
strong place aversion. 
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Figure 3.1 Behavioural effects of intra-BLA CB1R transmission on morphine-
related CPP 
(A) Dose response analysis of intra-BLA AM 251 (0, 50 and 500ng/0.5μl) versus sub-
reward threshold morphine (0.05 mg/kg) conditioning. While rats receiving vehicle (n=7) 
or 50ng/0.5μl group (n= ), showed no preference for sub-threshold morphine, rats 
receiving a higher dose of AM 251 (500ng/0.5μl, n= ), showed robust morphine CPP. 
Pretreatment with α-flu (0.8 mg/kg, n=7), blocked morphine reward potentiation. Intra-
BLA AM 251 alone (500ng/0.5μl, n=8) vs. vehicle produced neither preference nor 
aversions (far right). (B) Intra-BLA AM 251 (500ng, n=7) or vehicle controls (n=8) vs. a 
supra-threshold conditioning dose of morphine (5 mg/kg) both showed significant 
morphine CPP. (C) Dose-response analysis of intra-BLA WIN 55,212-2 (0, 50 and 
500ng/0.5μl) vs. sub-threshold morphine (0.05 mg/kg i.p.). Rats receiving intra-BLA 
vehicle (n =  ) or a lower dose of WIN 55 (50ng/0.5μl; n =  ) showed no CPP for 
morphine environments, rats receiving a higher dose of WIN 55,212-2 (500ng/0.5μl, n = 
7), showed significant CPA. Pretreatment of rats with α-flu (0.8 mg/kg, n=7), blocked 
morphine CPA. Control rats receiving WIN 55,212-2 (500ng/0.5μl, n = 8) vs. vehicle 
showed no environmental preferences (far right). (D) Bilateral intra-BLA WIN 55,212-2  
(500ng/0.5μl) switches a supra-reward threshold conditioning dose (5.0 mg/kg i.p.) of 
morphine into CPA. While vehicle controls (n=8) showed morphine CPP, rats receiving 
the WIN 55 (n=8), demonstrated morphine CPA. (E) Summary of bidirectional effects of 
AM 251 and WIN 55,212-2 (0, 50 and 500ng/0.5μl) on subthreshold dose of morphine 
presented as difference scores (time spent in drug minus saline environments). (F) 
Summary of bidirectional effects of AM 251 or WIN 55,212-2 vs. supra-reward threshold 
conditioning doses of morphine. * p < 0.05 and ** p < 0.01, for this and all subsequent 
figures.   
 
 
69 
 
3.3.3 NMDA receptor blockade in the NA shell selectively blocks the 
effects of intra-BLA Cb1R modulation of opiate reward processing 
We next examined the potential role of intra-NAc NMDA receptor transmission on the 
behavioral effects of intra-BLA CB1R activation or blockade. We first targeted the core 
region of the NAc (NACo) with bilateral microinfusions of the selective NMDA receptor 
antagonist, AP5 (see methods), using a dose (1g/0.5l) which we have previously 
reported produces no effects in and of itself on opiate reward processing (Lintas et al., 
2012). Fig. 3.2A,B represents a sample micrograph and schematic summary of intra-
NACo cannula placement. The first experimental group received bilateral intra-NACo 
microinfusions of AP5 (Fig. 3.2C,D) followed by intra-BLA WIN 55 (500ng/0.5μl) or 
vehicle, vs. the supra-reward threshold dose of morphine (5.0 mg/kg i.p.). Analysis of 
CPP scores revealed a significant effect of treatment on times spent in morphine vs. 
saline-paired environments (F(1,29)= 194.33, p<0.0001). Post hoc analyses revealed that 
both vehicle control and rats receiving intra-NACo AP5 showed significant aversions to 
normally rewarding conditioning doses of morphine (n’s= , p’s < 0.01; Fig. 3.2C).  
The next group received intra-NACo microinfusion of AP5, and an intra-BLA 
microinfusion of AM 251 (500ng/0.5μl) against the sub-threshold dose of morphine (0.05 
mg/kg i.p.). Analysis of CPP scores revealed a significant effect of treatment on times 
spent in morphine vs. saline-paired environments (F(1,27)= 172.83, p<0.0001; Fig. 3.2D). 
Post hoc analyses revealed that both groups showed significant potentiation of normally 
sub-reward threshold morphine conditioning CPP (n’s= , p’s<0.01), demonstrating that 
NMDA transmission in the NACo is not required for either the reward potentiating or 
aversion inducing effects of intra-BLA CB1R blockade, or activation, respectively. 
Next, to examine the potential role of the BLANASh pathway in CB1R-induced 
modulation of opiate motivation, rats received bilateral AP5 (1μg/0.5μl) intra-NASh (Fig. 
3.2G,H) prior to intra-BLA WIN 55 (500ng/0.5 μl), vs. the supra-reward threshold dose 
of morphine. Fig. 3.2E,F represents intra-NASh injector placement and a schematic 
summary showing bilateral NASh cannula placements.  Analysis of CPP scores revealed 
a significant interaction between group and treatment (F(1,29) = 73.38, p<0.0001; Fig. 
3.2G). Post hoc analyses revealed that whereas control rats displayed a robust morphine-
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environment aversion (n=7; p<0.01), rats receiving intra-NASh NMDA receptor 
blockade displayed neither preference nor aversion for either environment (n=7, p>0.05).  
Next, we challenged the effects of intra-BLA CB1R blockade on morphine reward 
potentiation vs. intra-NASh NMDA receptor blockade (Fig. 3.2H). Rats received intra-
NASh AP5 (1μg/0.5μl), prior to intra-BLA AM 251 (500ng/0.5μl) vs. the sub-reward 
threshold dose of morphine (n=7). Analysis of CPP scores revealed a significant 
interaction between group and treatment (F(1,27) = 54.37; p<.0001). Post hoc analyses 
revealed that whereas control rats receiving AM 251 showed a significant potentiation in 
normally sub-reward threshold morphine CPP (n=7 p<.01), rats receiving intra-NASh 
AP5 showed no preference for morphine-paired environments (n=7, p>.05). While we 
have demonstrated previously that intra-NASh AP5 (1g/0.5l) fails to block morphine 
reward in and of itself (Lintas et al., 2012), to rule out any possible motivational effects 
of intra-NASh AP5 alone, a control group (n=7) received intra-NASh AP5 alone vs. 
vehicle. Analysis of CPP scores revealed that AP5 alone, failed to produce any 
motivational effects during the CPP test (Fig 3.2H, t6=.98, p>.05).  Together, these 
results demonstrate that BLA CB1R-mediated modulation of opiate reward processing 
depends upon an excitatory BLANAc pathway, specifically targeting the NASh, and 
mediated via NMDA receptor transmission.  
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Figure 3.2 Effects of intra-NAc NMDA receptor blockade on intra-BLA CB1R-
mediated modulation of morphine reward and aversion behaviors 
(A) Microphotograph showing a typical intra-NACo injector placement. (B) Schematic 
summary of intra-NACo cannula placements:  = NACo placements for 1μg AP5 vs. 
500ng WIN 55 vs. supra-threshold morphine. * = NACo placements for 1μg AP5 vs. 
500ng AM 251 vs. sub-threshold morphine. (C) Intra-NACo NMDA receptor blockade 
fails to block the ability of intra-BLA WIN 55,212-2 (500ng/0.5μl, n = 8) to switch 
supra-reward threshold morphine CPP into conditioned aversions with both control (n=8) 
and WIN 55 groups (n=7) showing a significant CPA to morphine-paired environments 
(D) Intra-NACo NMDA receptor blockade (n = 7) fails to block the reward potentiating 
effects of intra-BLA AM 251 (n=7) during sub-reward threshold morphine conditioning, 
with both groups showing robust morphine CPP. (E) A microphotograph showing a 
typical intra-NASh injector placement. (F) A schematic summary of bilateral intra-NASh 
cannula placement: ☐= NASh cannula placements for intra-NASh AP5 vs. 500ng WIN 
55,212-2 vs. supra-threshold morphine.  = Bilateral NASh cannula placements for intra-
NASh AP5 vs. 500ng AM 251 vs. sub-threshold morphine. (G) Blockade of intra-NASh 
NMDA transmission blocks the ability of intra-BLA CB1R activation to switch morphine 
reward CPP into CPA. While control rats (n=8) showed normal CB1R-mediated 
morphine CPA, this effect was blocked in rats receiving intra-NASh NMDA receptor 
blockade (n=7). (H) Blockade of intra-NASh NMDA transmission completely blocks the 
ability of AM 251 (500ng/0.5μl, n =  ) to potentiate sub-reward threshold morphine 
relative to controls, who show normal reward potentiation effects (n=7). Furthermore, 
intra-NASh AP 5 (1μg/0.5μl) had no effect on it’s own (far right). 
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3.3.4 Intra-BLA CB1R blockade differentially modulates NASh MSN 
vs. FSI neuronal activity patterns depending on morphine reward 
salience 
Given our findings demonstrating a functional role for excitatory NMDA transmission 
within the NASh for the processing of intra-BLA CB1R-dependent effects on opiate 
reward behaviours (Fig. 3.2), we next analyzed the NASh with in vivo neuronal 
recordings to determine the potential effects of intra-BLA CB1R activation or blockade 
on NASh MSN vs. FSI neuronal activity dynamics (see methods, Fig. 3.3). A schematic 
and micrograph showing representative intra-NASh micro-wire placement is presented in 
Fig. 3.3A. Furthermore, the mean baseline firing frequency for MSN/FSI (Fig. 3.3B), and 
corresponding inter-spike interval histograms (Fig. 3.3C,D) for MSN vs. FSI neurons are 
depicted. Moreover sample MSN/FSI waveforms (Fig 3.3 E), an overlay (Fig. 3.3 F), 
and sample traces during recording are shown in Fig. 3.3 G,H respectively. 
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Figure 3.3 Histological analyses and characterization of NASh FSI vs. MSN 
neuronal sub-populations  
(A) Schematic of typical unilateral micro-wire NA shell placements for 500ng WIN 55 
vs. supra-threshold dose of morphine (blue lines), and microphotograph showing a 
typical intra-NASh microwire location (black arrow). (B) Mean FSI/MSN baseline firing 
frequency (C) A sample MSN inter-spike interval histogram. (D) A representative FSI 
inter-spike interval histogram. (E) Sample waveforms for MSN and FSI. (F) FSI/MSN 
waveform overlay. (G) A trace recording depicting FSI and MSN 
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We first examined the effects of sub-reward threshold morphine (0.05 mg/kg) CPP 
conditioning and memory recall in rats receiving intra-BLA vehicle microinfusions. Post-
experimental offline analyses of sorted NASh neuronal units in the intra-BLA vehicle 
group vs. sub-reward threshold morphine (0.05 mg/kg) revealed totals of n=45 MSN and 
n=49 FSI units recorded, while offline analyses of NASh neuronal populations from rats 
receiving intra-BLA AM 251 (500 ng/0.5 l) vs. sub-reward threshold morphine (0.05 
mg/kg) resulted in the analysis of n=20 FSI units and n=39 MSN units over the course of 
conditioning and CPP recall test phases. Analysis of MSN neuronal population activity 
over morphine trials for both intra-BLA vehicle and AM 251 animals, showed a 
significant interaction between group and treatment (F(8,53)=10.31, p<.0001; Fig. 3.4A). 
Post hoc analysis of vehicle MSN neuronal population activity comparing % change in 
frequency during morphine CPP conditioning trials relative to baseline, revealed no 
significant effects of conditioning on MSN firing frequencies across trials (p’s>.05). In 
contrast, post hoc analysis of CB1R blockade group revealed a significant decrease in 
MSN activity levels from baseline during all morphine conditioning trials (p’s<.01). 
Furthermore, comparing vehicle vs. AM 251 groups revealed rats receiving intra-BLA 
AM 251 showed significantly attenuated MSN activity levels relative to vehicle controls 
at all conditioning trials (p’s<.01). 
We next compared NASh FSI neuronal activity levels comparing intra-BLA vehicle vs. 
AM 251 groups during conditioning. One-way ANOVA comparing FSI morphine trial 
recordings across vehicle or AM 251 groups revealed a significant interaction between 
group and treatment (F(8,71)=61.96, p<.0001; Fig. 3.4B). Post hoc analyses of AM 251 
group revealed a significant increase in FSI firing rates during all morphine trials 
(p’s<.01), whereas the vehicle group showed no significant changes (p’s>.05). 
Furthermore, comparing vehicle vs. AM 251 groups revealed rats receiving intra-BLA 
AM 251 showed significantly increased FSI activity levels relative to vehicle controls 
during all trials (Trial 1, 3, 4=p’s<,01; Trial 2, p<.05).  
The behavioural CPP recall test showed that animals receiving intra-BLA vehicle (n=6) 
demonstrated no significant differences in times spent in saline vs. morphine 
environments (t5=.15, p>.05; Fig. 3.4C). In contrast, behavioural testing of animals 
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receiving intra-BLA AM 251 (n=7), revealed a significant CPP for morphine-paired 
environments (t6= 11.25, p<.0001; Fig. 3.4C). Moreover, corresponding neuronal 
population activity recording during the CPP recall test revealed no significant change in 
either FSI or MSN recordings from baseline for the vehicle control group. However, a 
divergent FSI vs. MSN population activity levels relative to normalized baselines during 
exposure to morphine-paired environments was observed for the intra-BLA AM 251 
group. Analysis revealed a significant effect of group and treatment (F(4,49)= 74.60, 
p<.0001; Fig. 3.4D). Post hoc analysis revealed a significant increase in FSI and a 
decrease in MSN for animals receiving intra-BLA AM 251 (p<.01), and no significant 
change from baseline for the intra-BLA vehicle group (p>.05). A sample neuronal 
rastergram showing the acute inhibitory effect of intra-BLA AM 251 (500ng/0.5 l) on 
spontaneous NASh MSN firing activity is presented in Fig. 3.4E. In contrast, the typical 
acute excitatory effect observed following intra-BLA AM 251 on the spontaneous 
activity of a representative NASh FSI neuron is presented in Fig. 3.4F.  
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Figure 3.4 Neuronal FSI vs. MSN population activity patterns during sub-reward 
threshold morphine (0.05 mg/kg) conditioning and recall testing: intra-BLA AM251 
(500ng/0.5μl) vs. vehicle controls.  
(A) Summary of MSN recordings during morphine trials revealed no significant changes 
from baseline for the intra-BLA vehicle group. However, a significant decrease in MSN 
population activity levels relative to pre-conditioning baseline was observed on all 
morphine conditioning trials for rats receiving intra-BLA AM 251(500ng/0.5μl). (B) 
Summary of FSI population activity recorded during sub-reward threshold morphine 
conditioning trials revealed no significant changes from baseline during conditioning 
trials for intra-BLA vehicle group. In contrast, rats receiving intra-BLA AM 251 showed 
a significant increase in FSI activity from baseline across all morphine conditioning 
trials. (C) Vehicle control rats showed no preference for vehicle vs. morphine-paired 
environments during CPP recall testing. However, intra-BLA CB1R blockade resulted in 
the potentiation of morphine reward CPP. (D) Neuronal population activity analyses 
during CPP recall testing indicted no changes in either FSI or MSN activity levels from 
pre-test normalized baselines for the vehicle control group. Conversely, neuronal FSI vs. 
MSN population activity recorded during CPP recall testing shows divergent FSI vs. 
MSN activity, an increase in FSI and a decrease in MSN activity for the intra-BLA AM 
251 group. (E,F) Representative MSN (E) and FSI (F) rastergrams showing 
representative 10 min neuronal activity level pre and post intra-BLA AM 251 
(500ng/0.5μl) microinfusions. 
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3.3.5 Intra-BLA CB1R activation differentially modulates NASh MSN 
vs. FSI neuronal activity patterns during morphine reward or 
aversion learning 
We next examined the effects of supra-reward threshold morphine (5.0 mg/kg; i.p.) CPP 
on NASh MSN vs. FSI neuronal populations in rats receiving intra-BLA vehicle (n=7) 
and intra-BLA WIN 55 (n=6). Post-experimental offline examination of isolated NASh 
neuronal populations for vehicle animals resulted in the analysis of n=61 MSN and n=64 
FSI and for animals receiving intra-BLA WIN 55 resulted in the analysis of n=31 FSI and 
n=24 MSN units analyzed over the course of conditioning and CPP test phases. Statistical 
analysis of MSN neuronal activity during morphine conditioning trials revealed a 
significant interaction between group and treatment (F(8,152)= 87.34, p<.0001; Fig. 3.5A). 
Post hoc analyses revealed significant increases in MSN population activity levels from 
baseline for the intra-BLA WIN 55 group during all morphine conditioning trials 
(p’s<.01), and a significant decrease in MSN activity for the 3rd and 4th morphine 
conditioning trial of vehicle controls (p’s<.05). Furthermore, comparing vehicle vs. WIN 
55 groups revealed that rats receiving intra-BLA WIN 55 showed significantly increased 
MSN neuronal activity levels relative to vehicle controls during all conditioning trials 
(p’s<.01).  
Next, analyses of FSI activity during conditioning trials across both vehicle and 
experimental group revealed a significant effect between group and treatment (F(8,206)= 
37.79, p<.0001; Fig. 3.5B). Post hoc analyses revealed significant decreases in FSI 
population activity levels during all conditioning trials for the intra-BLA WIN 55 group 
(p’s<.05), and a significant increase across all morphine trials for the vehicle control 
group (p<.05 for 1
st
 trial, p’s<.01 for the remaining trials). Furthermore, comparing 
vehicle vs. WIN 55 groups revealed rats receiving intra-BLA WIN 55 showed 
significantly decreased FSI neuronal activity levels relative to vehicle controls during all 
conditioning trials (p’s<.01). 
Intra-BLA vehicle control behavioral testing revealed a significant CPP for morphine-
paired environments (t6= 11.25, p<.0001; Fig. 3.5C). Consistent with previous findings 
(Fig. 3.1D), intra-BLA CB1R activation switched the normally rewarding effects of 
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morphine into a strong conditioned place aversion, with rats (n=6) demonstrating a robust 
morphine environment aversion during CPP testing (t5=12.74, p<0.001; Fig. 3.5C). 
Furthermore, corresponding neuronal population activity recording for both groups 
during the CPP recall test revealed divergent FSI vs. MSN population activity levels 
relative to normalized baselines during exposure to morphine-paired environments. 
Analysis revealed a significant effect of group and treatment on relative firing rates 
(F(4,109)= 57.13, p<.0001; Fig. 3.5D) with post hoc analysis revealing a significant 
increase in FSI neuronal activity vs. a significant decrease in MSN neuronal population 
activity levels for the vehicle control group, relative to normalized pre-test baseline 
levels, and the opposite was observed for intra-BLA WIN 55 group (p’s<.01, Fig. 3.5D). 
Moreover, a sample neuronal rastergram showing the acute excitatory effect of intra-BLA 
WIN 55 (500ng/0.5 l) on spontaneous NASh MSN firing activity is presented in Fig. 
3.5E. In contrast, the typical acute inhibitory effect following intra-BLA WIN 55 on the 
spontaneous firing activity of NASh FSI neurons is demonstrated in the sample neuronal 
rastergram presented in Fig. 3.5F. Thus, the effects of intra=BLA CB1R activation on 
switching morphine reward CPP into CPA, were associated with divergent NASh 
neuronal effects on MSN vs. FSI population activity: supra-threshold morphine reward 
CPP acquisition and recall was associated with decreased MSN neuronal activity and 
increased FSI activity, whereas the CB1R-mediated switch from reward to aversion 
processing was associated with the opposite pattern of NASh neuronal population 
activity. 
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Figure 3.5 Neuronal FSI vs. MSN population activity patterns during supra-reward 
threshold morphine (5.0 mg/kg) conditioning and recall testing: intra-BLA WIN 
55,212-2 (500ng/0.5μl) vs. vehicle controls. 
(A) Intra-BLA CB1R activation resulted in a significant increase in MSN activity in 
comparison to baseline levels across all four morphine conditioning trials. Conversely, 
for the intra-BLA vehicle control group, a significant decrease in MSN population 
activity levels relative to pre-conditioning baseline was observed on conditioning trials 1, 
3 and 4. (B) A significant decrease in FSI neuronal activity from baseline was observed 
in rats receiving intra-BLA WIN 55,212-2 (500ng/0.5μl) during morphine reward 
conditioning trials. In contrast, FSI neuronal population activity is significantly increased 
relative to normalized pre-conditioning baseline levels during all morphine trials. (C) 
Vehicle control rats show a robust CPP for environments paired with supra-threshold 
morphine, while BLA CB1R activation produces a significant morphine CPA. (D) 
Neuronal FSI vs. MSN population activity recorded during CPP recall testing shows 
divergent FSI vs. MSN activity, similar to that observed during conditioning trials. Intra-
BLA vehicle controls show increased FSI neuronal activity and a decrease in MSN 
neuronal activity from baseline. In contrast, intra-BLA CB1 activation causes decreased 
FSI and increased MSN neuronal activity from baseline. (E,F) Sample MSN (E) and FSI 
(F) rastergrams depicting representative single neuron responses during 10 min neuronal 
activity recordings pre and post intra-BLA CB1R activation with WIN 55 (500ng/0.5l).  
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3.4 DISCUSSION 
The present findings add to a growing body of evidence demonstrating that bi-directional 
modulation of CB1R transmission can modulate both rewarding and aversion-related 
emotional processing (Ahmad et al., 2013; Laviolette and Grace, 2006; Tan et al., 2014). 
Within the mammalian amygdala, CB1Rs are primarily localized to the BLA, but absent 
in adjacent nuclei such as the central nucleus (Katona et al., 2001). Endocannabinoid 
signaling within the BLA is involved critically in affective processing (Hill and Patel, 
2013). Functionally, BLA CB1R transmission has been shown to modulate feedforward 
inhibitory presynaptic GABA release and can therefore tightly regulate the excitability of 
BLA output neurons (Katona et al., 2001). Consistent with the present findings, studies 
using systemically applied CB1R agonists or antagonists have demonstrated that CB1R 
transmission can control functional outputs to the NASh. For example, Pistis et al. (2004) 
reported that BLANASh projection neurons were strongly inhibited by WIN 55 
administration. Furthermore, BLA-evoked excitatory responses in recorded NASh 
neurons were similarly inhibited by systemic CB1R agonists, suggesting that activation 
of CB1R signaling can dampen BLA-dependent excitation of NASh neurons. While these 
studies examined single unit neuronal responses with systemic drug administration, the 
present findings are the first study to combine direct intra-BLA CB1R pharmacological 
activation or blockade, with simultaneous multi-unit neuronal population recordings in 
the NASh and post-experimental dissociation of FSI vs. MSN neuronal activity patterns.  
We found that the ability of BLA CB1R-blockade to potentiate the reward salience of 
normally sub-reward threshold morphine conditioned effects was associated with 
concomitant inhibition of MSN and activation of FSI neurons during conditioning and 
recall phases of morphine-related learning. In contrast, BLA CB1R activation, which 
switched morphine CPP into CPA behaviors, was associated with the opposite pattern of 
NASh neuronal population activity. Importantly, BLA CB1R-mediated modulation of 
NASh FSI vs. MSN neuronal population activity was not simply an effect of acute intra-
BLA CB1R blockade or activation, as the same reward vs. aversion-related patterns of 
MSN/FSI population activity were present during the drug-free memory recall phase, in 
the absence of any intra-BLA CB1R modulation. 
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Our results are consistent with evidence demonstrating that reward processing within the 
NAc is linked to inhibition of MSN neurons, while aversion-related processing is linked 
to their activation. For example, several studies using single-unit electrophysiological 
recordings in the NAc have reported that the reinforcing effects of drug self-
administration are correlated with transient inhibitory effects on NAc neurons, including 
studies using heroin (Chang et al., 1997), cocaine (Peoples and West, 1996; Peoples et 
al., 2007) and naturally rewarding stimuli such as food or sucrose (Carelli et al., 2000; 
Nicola et al., 1999) as conditioning cues.  A consistent finding across these studies is that 
the most commonly observed pattern of MSN reward-related firing is transient inhibition 
(for review see Carlezon and Thomas, 2009). Furthermore, systemically or intra-VTA 
applied opiates such as morphine or heroin have been reported to induce inhibitory 
effects in a plurality of sampled NAc neurons (Hakan and Henriksen, 1987; 1989; Lee et 
al., 1999), however these studies did not differentiate between putative FSI vs. MSN 
neuronal subtypes, which appear to play distinct roles in the associative effects of either 
rewarding or aversion-related emotional processing (Lansink et al., 2010; Sun and 
Laviolette, 2015). 
Given that intra-BLA and intra-PFC CB1 activation has been shown to strongly 
potentiate normally non-salient, fear-related associative memories (Draycott et al., 2013), 
one possibility is that BLA CB1R signaling may induce a general state of negative 
emotional bias by activating NASh MSN neuronal populations. Indeed, activation of 
MSN neuronal populations has been linked previously to aversive emotional processing. 
For example, studies examining the processing of taste aversion learning demonstrated 
that a majority of NAc neurons displayed excitatory vs. inhibitory response patterns 
(Roitman et al., 2005; Wheeler et al., 2008). Furthermore, modulating the motivational 
valence of appetitive (saccharin) taste cues from rewarding to aversive (by inducing 
cocaine-related conditioned taste aversions), switched the predominant neuronal response 
pattern from inhibitory to excitatory, suggesting that dynamic switches between reward 
vs. aversive-related processing may be related to shifts between excitatory vs. inhibitory 
NAc neuronal response patterns (Wheeler et al., 2008). Furthermore, manipulation of 
specific molecular signaling pathways within the NAc which in turn increase the general 
excitability of NAc neurons, have been shown to switch the motivational valence of 
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conditioning stimuli from rewarding, to aversive (Carlezon and Thomas, 2009). For 
example, overexpression of CREB within the NAc, which potentiates intrinsic NAc 
neuronal excitability (Dong et al., 2006), was able to switch the rewarding conditioning 
effects of cocaine, into aversions, while simultaneously inducing depressive-like 
behaviors (Pliakas et al., 2001). 
While few studies have examined the effects of reward or aversion-related processing on 
NASh FSI unit activity, it has been reported that dopamine receptor activation can induce 
FSI unit hyperpolarization (Centonze et al., 2003) and similarly, amphetamine 
administration strongly potentiates NAc FSI unit activity recorded in vivo (Wiltschko et 
al., 2010). Given our observations that intra-BLA CB1R blockade strongly potentiated 
the reward salience of normally sub-threshold morphine conditioning doses, through a 
DA-dependent mechanism, this may suggest that BLA-mediated modulation of NAc 
neuronal activity may involve modulation of DA release within the NASh, via 
convergent inputs onto NMDA receptor substrates, consistent with previous reports 
showing that the BLA modulates NAc neuronal activity rates via convergent NMDA and 
DA receptor mechanisms (Floresco et al, 2001). 
In summary, the present study demonstrates that cannabinoid modulation of amygdala 
inputs to the NAc, is capable of powerfully disrupting the processing of affective 
information through both GLUTergic and DAergic mechanisms within the NASh. In 
summary, the present findings reveal a novel mechanism by which cannabinoid 
dysregulation within the amygdala may lead to disturbances in affective regulation by 
altering both the salience and valence of associative cues related to affective processing 
via NAc neuronal populations. 
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tegmental area is differentially mediated through dopamine 
projections to the basolateral amygdala or nucleus accumbens 
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4.1 INTRODUCTION 
Dopamine (DA) neurons are the major components of the brain’s reward circuitry and 
mediate the salience of stimulus reward learning (Berridge & Robinson, 1998; Flagel et 
al., 2011b). The ventral tegmental area (VTA) contains a high density of DA neurons and 
sends DA efferent to higher level cortical structures that include the prefrontal cortex 
(PFC), basolateral amygdala (BLA), and nucleus Accumbens (NAc) which form an 
interconnected network that is crucial for reward related learning (Grace et al., 2007; 
Ikemoto & Panksepp, 1999).  Drugs of abuse such as nicotine, cannabis, opiates, and 
cocaine have all been known to exert their effects through the dopamine reward pathway, 
often altering mesolimbic DA levels (Everitt & Wolf, 2002; Kelley & Berridge, 2002; 
Koob, Sanna, & Bloom, 1998; R. a. Wise, 1996). Cannabinoid CB1 receptors in 
particular have shown to modulate DA activity. Systemic administration of THC has 
shown to excite DA neurons and increase DA firing rate in both the VTA and substantia 
nigra (French et al., 1997).  
More recent studies have shown that DA neurons localized specifically in the posterior 
region of the VTA (PVTA) is responsible for reward related learning. Nicotine and 
opiates have been found to be significantly more rewarding when administered in the 
PVTA rather than the anterior region of VTA (AVTA) (Ikemoto & Wise, 2002). Zangen, 
Solinas, Ikemoto, Goldberg, & Wise (2006), have shown that THC infusions into the 
PVTA produced a rewarding effect, while THC infusions in the AVTA produced no 
effects. Although it is known that cannabinoid activation does produce a behavioural 
effect, the specific pathways involved in the cannabinoid related reward are unknown. 
Since the PVTA sends DAergic projections to both the BLA and specifically the shell 
region of the NAc (NASh) (Bassareo & Di Chiara, 1997), we wanted to further 
investigate the possible mechanisms by which cannabinoid reward effects are processed 
through VTA DAergic outputs. In the present study, we investigated the role of CB1 
receptor activation and blockade in the PVTA in relation to cannabinoid related reward 
and aversion signals, using an unbiased condition place preference (CPP) paradigm in 
conjunction with behavioural pharmacology. We report that intra-PVTA CB1 activation 
produced a cannabinoid reward CPP, while CB1 blockade of intra-PVTA produced a 
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cannabinoid related aversion during the recall phase. Furthermore, the DA antagonist α-
flu microinfused intra-BLA, blocked the cannabinoid reward CPP, but not the aversion. 
In contrast, intra-NASh microinfusion of α-flu blocked the cannabinoid related aversion 
but not the reward. Thus, cannabinoid related reward and aversion signals are mediated 
through DAergic PVTABLA and PVTANASh functional pathways. 
4.2 MATERIALS AND METHODS 
4.2.1 Animals and Surgery 
All procedures performed in the study were in accordance with the Canadian Council on 
Animal Care and approved by Western University’s Animal Care Council. Adult male 
Sprague Dawley rats (350-400 gm; Charles River Canada) were anesthetized with an 
intraperitoneal injection (i.p.) of a ketamine (80mg/ml)-xylazine (6mg/kg) mixture, and 
placed in a stereotaxic device. For double cannulation in the PVTA, two stainless steel 
guide cannulae (22 gauge) were implanted into the PVTA using the following 
coordinates (10° angle): from bregma, anteroposterior (AP) -5.5mm, lateral (LAT) 
±2.3mm, Ventral (V) -8.0mm from the dural surface. The following coordinates were 
used for AVTA cannulation (10° angle): AP -4.5mm, LAT ±2.3mm, V -8.0mm from the 
dural surface.  For quadruple cannulation in the BLA-PVTA, two additional cannulae 
were implanted in the BLA using the following coordinates (0° angle): from bregma, AP 
-2.6 mm, LAT ±5.0 mm, and V -7.2 mm from the dural surface. For quadruple 
cannulation in the NASh-PVTA, the two additional cannulae in the NASh were 
implanted with the following coordinates (12° angle): from bregma, AP +1.8 mm, LAT 
±2.6 mm, and V - .4 mm from the dural surface. Dental acrylic and jeweler’s screws 
were used to secure the cannulae in place. 
4.2.2 Drug Treatment 
The CB1 agonist WIN 55,212-2 (Tocris Bioscience) and antagonist AM 251 (Tocris 
Bioscience) were dissolved in dimethyl sulfoxide (DMSO), and diluted in physiological 
saline (pH adjusted to 7.4) when necessary to obtain the appropriate doses (50ng and 
500ng).  Bilateral PVTA or AVTA micro-infusions (μg/0.5μl) were performed over a 
period of 1 minute via plastic tubing connected to a 1μl Hamilton micro-syringe. 
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Injectors were left in place for an additional 1 minute to ensure adequate diffusion of the 
drug from the injector tip. The dopamine (DA) receptor antagonist α-Flupenthixol 
dehydrochloride (α-flu, Tocris Bioscience) was also dissolved in physiological saline (pH 
7.4). For DA antagonist treatment, animals received bilateral BLA or NASh 
microinfusions of α-flu (1μg/0.5μl) prior to receiving intra-PVTA microinfusions of CB1 
agonist or antagonist. 
4.2.3 Condition Place Preference 
All rats were conditioned using the unbiased classical Pavlovian conditioning method 
condition place preference (CPP), which differentiates between two distinct environments 
as described previously(Bishop et al., 2011; Steven R Laviolette & van der Kooy, 2004). 
The two environments used for conditioning varied in smell, texture and colour. One 
environment was a black box, with a smooth Plexiglass floor wiped down with 2% acetic 
acid prior to each conditioning session. The other environment was a white box, with a 
wire mesh floor covered with aspen woodchips. Rats have shown no baseline preference 
for either of these two boxes (S R Laviolette & van der Kooy, 2003). To adapt the 
animals to the confinement of these boxes, they were placed in a neutral grey box of the 
same dimensions for a period of 20 minutes, 24 hours prior to start of the conditioning. 
During the acquisition phase, animals are conditioned for a period of 8 days 
counterbalanced between drug and saline paired environments. During the conditioning 
sessions (in the PVTA or AVTA experiments), animals received bilateral intra-PVTA or 
intra-AVTA microinfusions of either CB1 agonist, antagonist or saline. Rats are then 
placed in a drug-paired environment or saline-paired environment alternated over 8 days. 
During the recall phase, animals are tested drug free, 3-4 days after conditioning. The box 
used for testing is a combination of the two environments separated by a grey neutral 
zone in the middle. The animal is placed in the grey zone and allowed to move freely for 
a period of 10 min between the two environments. The time spent in each environment is 
then recorded and analyzed. 
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4.2.4 Histology 
At the completion of each experiment, animals were anesthetized with a uthanyl solution 
and perfused with isotonic saline followed by 10% formalin. Brains were extracted, 
sliced at 60 μm, and stained with cresyl violet to allow for histological analysis of 
injection sites. Using light microscopy, location of injector placements is analyzed and 
any animal with misplaced guide cannulae was excluded from the study. 
4.2.5 Data Analysis 
Data were analyzed with either a student’s t-test or two-way analysis of variance 
(ANOVA) where appropriate. Post hoc analyses were performed with Newman-Keuls 
and Fisher’s least significant difference test. 
4.3 RESULTS 
4.3.1 Histological analysis 
 Histological analysis indicated injector cannulae placements to be bilaterally localized 
within the anatomical boundaries of the PVTA, AVTA, BLA and NASh region, as 
determined by the Atlas of Paxinos and Watson (2007). Fig. 4.1A, shows a sample 
micrograph representing intra-PVTA micro-injector placement and Fig.4.1B shows a 
schematic of bilateral intra-PVTA microinjection placements for the CB1 agonist and 
antagonist groups. The micrograph of the micro-injector placement of the anterior region 
of the VTA is illustrated in Fig. 4.2A, and the corresponding schematic representing 
bilateral intra-AVTA microinjection placement if shown in Fig. 4.2B. In Fig. 4.3A and B, 
we present a microphotograph showing a representative injector placement within the 
BLA and a schematic illustration showing a representative intra-BLA bilateral cannulae 
placements for the α-flu experiments. Fig. 4.4A, shows a micrograph representing intra-
NASh micro-injector placement indicated by black arrows and in Fig. 4.4B, we present a 
schematic of bilateral intra-NASh microinjection placement. 
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4.3.2 Microinfusion of CB1 agonist in the posterior region of the VTA 
produced a cannabinoid reward CPP 
The experiments performed in this study, all used the unbiased condition place preference 
(CPP) paradigm as outlined earlier in the materials and method section. To determine the 
potential role of CB1 receptor activation in the posterior region of the ventral tegmental 
area (PVTA), we performed bilateral intra-PVTA microinfusions of either saline or CB1 
agonist WIN 55,212-2 (WIN55, 50 or 500ng/0.5μl). Two-way ANOVA revealed a 
significant interaction between group and treatment  (F(1,27) =  92.14; p < .0001) on time 
spent in either the saline or  drug paired environment during the recall phase. Post hoc 
analysis revealed that the higher dose of WIN55 (500ng/0.5μl), produced a significant 
cannabinoid related reward, with animals showing a strong preference for the WIN55 
paired environment over the saline paired environment (n=7, p< .01, Fig. 4.1C). 
However, the animals receiving bilateral intra-PVTA WIN55 at the lower dose 
(50ng/0.5μl) showed no preference for either the saline or drug paired environment (n=7, 
p> .05, Fig. 4.1C). Hence, since the effective dose at which a cannabinoid reward is 
observed was the higher dose, all subsequent experiments involving WIN55, the dose of 
500ng/0.5μl was used. 
4.3.3 Intra-PVTA CB1 blockade produced a cannabinoid related 
aversion 
 The selective CB1 receptor antagonist AM 251 was used to block cannabinoid 
transmission in the PVTA. To examine the effects of AM 251, two doses of 50 or 
500ng/0.5μl were bilaterally microinfused intra-PVTA in two groups of animals against 
saline. Statistical analysis showed a significant interaction between group and treatment 
(F(1,31) = 176.18; p < .0001) for time spent in either of the two environments during the 
testing phase. Post hoc analysis revealed that animals receiving the higher dose of AM 
251 (500ng/0.5μl), spent a significantly longer time in the saline paired environment over 
the AM 251 paired environment, in turn demonstrating an AM 251 aversion (n=8, p< 
.01, Fig. 4.1D). Rats receiving the lower dose of AM 251, spent approximately equal 
amounts of time in both the saline or AM 251 paired environment and hence showed no 
preference for either environments as summarized in Fig. 4.1D (n=8, p> .05). Thus, for 
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all subsequent experiments involving AM 251, the effective dose of 500ng/0.5μl was 
used. 
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Figure 4.1 Bi-directional effects of intra-PVTA CB1 agonist and antagonist and 
PVTA histological analysis 
(A) Micrograph of a typical intra-PVTA injector placement. (B) Schematic summary of 
intra-PVTA cannula placement:       = PVTA placements for 500ng/0.5µl WIN 55 vs. 
Saline;       = PVTA placements for 500ng/0.5µl AM 251 vs. Saline. (C) Intra-PVTA 
microinfusion of 50-500ng/0.5µl WIN 55,212-2 vs. saline; the group with the lower dose 
of CB1 agonist (50ng/0.5µl, n=7), showed no preference for either the saline or WIN 55 
paired environment, while the group receiving the higher dose of WIN 55 (500ng/0.5µl, 
n=7) demonstrated a strong preference for the WIN 55 paired environment over the saline 
paired environment. (D) CB1 antagonist microinfusions intra-PVTA (50-500 ng/0.5µl); 
rats receiving 50ng/0.5µl AM 251 (n=8) showed no preference for either of the two 
environment. In contrast, animals receiving 500ng/0.5µl AM 251 intra-PVTA (n=8), 
displayed a significant preference for the saline paired environment over the AM 251 
paired environment. (E) Intra-PVTA microinfusion of a mix of WIN 55 and AM 251 
(500ng/0.5µl, n=7) showed no cannabinoid related reward or aversion. Hence when 
combined CB1 agonist and antagonist cancel out the earlier observed effects. * denotes 
p<.05 and ** denotes p<.01 for this and all subsequent experiment. 
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4.3.4 Co-administration of Intra-PVTA CB1 agonist and antagonist 
microinfusion produced no cannabinoid related reward or aversion 
 Given the opposing effects observed in the PVTA with separate administration of CB1 
agonist and antagonist, we wanted to examine the effects of WIN55 and AM 251 
combined. We microinfused intra-PVTA, a combination of WIN55 and AM 251 
(500ng/0.5μl) simultaneously against saline, during the conditioning sessions. Our results 
from the testing phase indicate that rats showed no preference for either the saline or the 
combined drug paired environment (n=7; t6=1.48, p= .19, Fig. 4.1E). Therefore, it 
appears that WIN55 and AM 251 combined, cancel out the individual cannabinoid 
reward and aversive effects observed earlier. 
4.3.5 Microinfusions of CB1 agonist and antagonist in the anterior 
region of the ventral tegmental area produced no behavioural 
effects 
 Given our earlier findings that CB1 receptor activation and blockade produced a 
cannabinoid related reward and aversion (Fig.1C and D), we next examined the potential 
effects of CB1 agonist and antagonist in the anterior region of the ventral tegmental area 
(AVTA). We performed bilateral intra-AVTA microinfusions of WIN55 (500ng/0.5μl) 
versus saline. Our results indicate that unlike the cannabinoid related reward CPP 
observed with intra-PVTA microinfusions of WIN55 (500ng/0.5μl), animals receiving 
the CB1 agonist in the AVTA showed no significant preference for either the saline 
or drug paired environment (n=8, t7=2.30, p= .06; Fig.2C). Similarly, blockade of CB1 
receptors in the AVTA with AM 251 (500ng/0.5μl), produced no cannabinoid related 
reward or aversion, with animals showing no preference for either the saline or the 
AM 251 paired environment (n=7, t6=0.22, p= .83; Fig.2C). Thus, the cannabinoid 
related reward and aversion with WIN55 and AM 251 is only expressed in the 
posterior region of the VTA and not the anterior region of the VTA. 
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Figure 4.2 Histological analysis and effects of CB1 agonist and antagonist in the 
AVTA 
(A) Sample micrograph of an intra-AVTA injector placement. (B) Intra-VTA cannula 
placement schematic summary:      = intra-AVTA placements for WIN 55 (500ng/0.5µl) 
vs. saline;       = intra-AVTA placements for AM 251 (500ng/0.5µl) vs. saline. (C) The 
group of animals receiving intra-AVTA CB1 agonist (500ng/0.5µl, n=8) showed no 
cannabinoid related CPP. Similarly, rats receiving intra-AVTA CB1 antagonist 
(500ng/0.5µl, n=7) also showed no preference or aversion to either the saline or drug 
paired environment. 
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4.3.6 Cannabinoid related reward learning depends upon dopaminergic 
transmission within the PVTA-BLA pathway 
Previous research has indicated that the VTA sends major Dopaminergic (DAergic) 
projections to both the basolateral amygdala (BLA) and the Nucleus accumbens (NAc) 
(Ford, Mark, & Williams, 2006) . To determine if the cannabinoid related reward CPP  
(WIN55) and the cannabinoid related aversion (AM 251) observed earlier as summarized 
in Fig. 4.2 B and C, are dependent on the PVTABLA DAergic pathway, we performed 
quadruple cannulations (see material and methods). Our first group of animals received 
bilateral microinfusions of the DA antagonist α-flu (1μg/0.5μl) intra-BLA, followed by a 
bilateral intra-PVTA microinfusion of either saline or WIN55 (500ng/0.5μl). Two way 
ANOVA comparing our α-flu/WIN55 group to our earlier group of WIN55 alone (Fig. 
4.1C), showed a significant interaction between group and treatment on the time spent in 
the saline or drug paired environment (F(1,27) = 80.22; p < .0001). Post hoc analysis 
indicated that the group of animals that received intra-BLA α-flu (1μg/0.5μl) prior to 
intra-PVTA WIN55 (500ng/0.5μl) microinfusions displayed no significant cannabinoid 
related reward CPP (n=7, p> .05; Fig. 4.3C), while the group of animals receiving only 
intra-PVTA WIN55 (500ng/0.5μl), showed a significant preference for the WIN55 paired 
environment (n=7, p< .01; Fig. 4.1C). Thus blocking the DAergic projection to the BLA, 
successfully blocked the cannabinoid reward CPP.  
Next, to examine the possible effects of α-flu on cannabinoid related aversion, we 
microinfused α-flu (1μg/0.5μl) directly into the BLA, followed by intra-PVTA 
microinfusions of either AM 251 (500ng/0.5μl) or saline. Statistical analysis indicated 
that animals in this group still displayed the cannabinoid related aversion observed earlier 
(Fig. 4.1D), with rats showing a significant preference for the saline paired environment 
(n=8, t7=7.89, p< .0001; Fig. 4.3C, far right). Hence, blocking DAergic projections in the 
BLA had no effect on cannabinoid related aversion. 
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Figure 4.3 Blockade of DA projections to the BLA and histological analysis of the 
BLA 
(A) Micrograph representing a typical intra-BLA injector placement. (B) Schematic 
summary illustrating intra-BLA cannula placement:    = BLA placements for α-flu 
(1µg/0.5µl) vs. intra-PVTA CB1 agonist (500ng/0.5µl);    = BLA placements for 
1µg/0.5µl α-flu vs. 500ng/0.5µl AM 251. (C) Blocking the DA projection from the 
PVTA to the BLA, successfully blocked the WIN 55 related reward CPP observed 
with intra-PVTA microinfusion of CB1 agonist (500ng/0.5µl, n=7). However, 
blocking DA intra-BLA, had no effects on intra-PVTA microinfusion of AM 251 
(500ng/0.5µl, n=8), as animals were still displaying a significant preference for the 
saline paired environment. 
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4.3.7 Cannabinoid related aversion is mediated through the PVTA-
NASh DAergic pathway 
The VTA has been implicated to regulate DA release in the NAc and the shell region of 
the NAc (NASh) has been shown to be involved in aversive motivation. To investigate 
the potential role of the DAergic projections to the NASh, we administered α-flu 
(1μg/0.5μl) bilaterally directly into the NAsh, followed by intra-PVTA microinfusions of 
either AM 251(500ng/0.5μl) or saline. Two-way ANOVA indicates a significant 
interaction between group and treatment (F(1,31) = 36.01; p < .0001) on times spent in 
saline and drug paired environment during the recall phase. Post hoc analysis revealed 
that animals receiving the α-flu prior to the CB1 antagonist showed no preference for 
either of the two environments (n=8, p> .05; Fig. 4.4D), while rats that only received the 
CB1 antagonist showed a significant preference for the saline paired environment over 
the AM 251 paired environment, displaying a cannabinoid related aversion (n=8, p< .01; 
Fig. 4.4D, far left). Therefore, α-flu successfully blocked the aversion observed earlier 
(Fig. 4.1D) with AM251.  
 Subsequently, to examine the effects of blocking DA in the NASh in conjunction with 
CB1 agonist administration; we microinfused α-flu (1μg/0.5μl) intra-NASh, followed by 
intra-PVTA microinfusions of WIN55 (500ng/0.5μl). Statistical analysis showed that rats 
in this group showed a significant preference for the WIN55 paired environment (n=8, 
t7=9.54, p< .0001; Fig. 4.4D, far right), much like the group that did not receive DA 
antagonist (Fig. 4.1C). Hence, α-flu in the NASh, had no effect on cannabinoid reward 
CPP. 
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Figure 4.4 Histological analysis of the NASh and the effects of blocking DA 
projections to the NASh on CB1 agonist and antagonist intra-PVTA microinfusion.  
A. Sample micrograph of intra-NASh injector placement. B. Intra-NASh cannula 
placement:     = NASh placements for the group of animals receiving intra-NASh α-flu 
(1µg/0.5µl) vs. AM 251 (500ng/0.5µl);      = NASh placements for intra-NASh α-flu 
(1µg/0.5µl) vs. WIN 55 (500ng/0.5µl). C. Blocking the DA projections in the intra-
PVTA-NASh pathway, successfully blocked the cannabinoid related aversion with intra-
PVTA AM 251 (500ng/0.5µl, n=8), as animals showed no aversion towards either 
environment. Conversely, blocking DA projections intra-PVTA-NASh pathway had no 
effect on cannabinoid related reward with intra-PVTA WIN55 microinfusion 
(500ng/0.5µl, n=8), as rats showed a strong preference for the drug environment over the 
saline environment, and hence a cannabinoid reward CPP. 
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4.4 DISCUSSION  
 A large body of literature has suggested a functional interaction between cannabinoids 
and DA. The cannabinoid system plays a major role in mediating neuronal excitability, 
inhibition and synaptic transmission, and most of CNS cannabinoid activity is regulated 
by the CB1 receptor (CB1R). Animal research has indicated that activation of the CB1R 
with an exogenous cannabinoid agonist, have been shown to inhibit presynaptic 
GLUTergic transmission in the VTA (Melis et al., 2004). Furthermore, both systemic and 
intra-cranial administrations of the highly potent CB1R agonist WIN 55 has been shown 
to regulate DA neurotransmission in several midbrain sub-regions (Ahmad, Lauzon, de 
Jaeger, & Laviolette, 2013; Fanarioti et al., 2014). Similarly, electrophysiological studies 
using HU210 (potent cannabinoid agonist), WIN 55, and THC (active ingredient in 
marijuana) have shown a robust increase in DA firing rate within the VTA (Cheer, 
Kendall, Mason, & Marsden, 2003; Gessa, Melis, Muntoni, & Diana, 1998; Wu & 
French, 2000). The VTA is the main site of DA neurons, however the DA neurons 
involved in the reward learning pathway are mostly localized within the posterior region 
of the VTA (PVTA); studies have shown that opiate related reward (Zangen, Ikemoto, 
Zadina, & Wise, 2002) and cannabinoid related reward (Zangen et al., 2006) are 
expressed when microinjected into the  PVTA, and not the AVTA. Taken together, these 
findings support our results that WIN55 microinfused intra-PVTA, dose dependently 
produced a cannabinoid reward CPP (Fig. 4.1C). In contrast, WIN55 administered intra-
AVTA produced no rewarding effects (Fig. 4.2C).  
 In terms of CB1 blockade, antagonism of CB1R located on both inhibitory and excitatory 
axon terminal target the midbrain DA system; blocking CB1R has shown to reduce cue-
induced reinstatement of drug seeking behaviour (Lupica & Riegel, 2005) and block 
extinction of conditioned taste aversion (Kobilo, Hazvi, & Dudai, 2007). The potent 
CB1R antagonist AM 251 has been shown to significantly suppress food intake 
(Chambers, Koopmans, Pittman, & Sharkey, 2006), reduce food-seeking behaviour  
(Chambers, Sharkey, & Koopmans, 2004), and inhibit methamphetamine self-
administration in rats (Vinklerová, Nováková, & Sulcová, 2002). However, the direct 
effects of CB1 antagonist within the VTA are not well documented. Our findings 
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illustrated that intra-PVTA AM 251 microinfusion, dose dependently produced a 
cannabinoid related aversion (Fig. 4.1D), while having no rewarding or aversive effects 
when administered intra-AVTA (Fig. 4.2C).  
 To further analyze the observed effects with WIN55 and AM 251, we examined the DA 
projections from the PVTA to the BLA and NASh. The BLA plays a crucial role in 
memory and learning processes, and hence a major component in the reward pathway and 
behavioural output. Intracellular recordings have shown that stimulation of PFC, inhibits 
behavioural output by activating GABAergic interneurons within the BLA (Grace & 
Rosenkranz, 2002). Furthermore, the BLA mediates DA efflux to the PFC, originating 
from the VTA (Phillips, Ahn, & Howland, 2003), drugs of abuse such as opiates share 
the common VTA-BLA-NAc pathway (Feltenstein & See, 2008), and DA projections 
from the VTA have shown to influence rewarding and emotional behaviour by 
modulating BLA-evoked changes in the PFC (Floresco & Tse, 2007). We found that by 
blocking DA projections within the BLA, we blocked the cannabinoid related reward 
observed with WIN55 (Fig. 4.3C). Conversely, inhibiting DA neurons in the BLA, had 
no effects with the cannabinoid related aversion induced by intra-PVTA microinfusion of 
AM 251(Fig. 4.3C, far right). Thus DA efferent in the PVTABLA pathway mediates 
the rewarding properties of CB1R activation, but has no effects on the aversive properties 
of CB1 antagonism. Activation of CB1R, inhibits GABA release (Katona et al., 2001), 
and in turn prolongs DA level activation in the PVTABLA  mesolimbic pathway, 
resulting in a behavioural output of cannabinoid related reward CPP.  
 Since the PVTA sends DA projections to multiple brain areas that serve various 
functions, the DA neurons also respond differently based on areas they innervate. To 
account for the cannabinoid related aversion, we examined the PVTANASh pathway. 
Lammel, Ion, Roeper, & Malenka (2011) have shown that DA cells projecting to the 
NASh responds to both rewarding and aversive stimulus. Furthermore, a review 
presented by Murray & Bevins (2010) showed that cannabinoid can present their effects 
in both positive and negative signals; whereas low doses of THC elicited a cannabinoid 
reward CPP, a higher dose of THC produced a conditioned place aversion (Elsmore & 
Fletcher, 1971). Our findings show that blocking DA neurons within the NASh, blocked 
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the cannabinoid related CPA induced by intra-PVTA AM 251 microinfusions (Fig. 
4.4C), while having no effect on cannabinoid related reward CPP. These results suggest 
that aversive stimuli are processed through the PVTANASh pathway. Previous 
pharmacological research indicates that CB1 activation promotes an increase in the 
CREB cycle in the NASh, promoting reward related behaviour such as CPP (Barrot et al., 
2011). However, deactivation of CB1R, would lead to a decrease in the CREB cycle, 
modulating DA neurons, suppressing reward, and resulting in an aversion response. This 
parallels our findings of the CB1 antagonist AM 251 intra-PVTA microinfusion resulting 
in a cannabinoid related aversion. 
4.5 CONCLUSION 
In summary, we report that intra-PVTA microinfusions of WIN 55,212-2 dose-
dependently produced a cannabinoid reward CPP, while intra-PVTA microinfusions of 
the CB1 antagonist AM 251 produced a cannabinoid related CPA. Neither of these 
effects was observed when repeated in the AVTA, supporting the notion that reward 
related learning is primarily conducted through the PVTA region. The intra-PVTA 
cannabinoid reward CPP and CPA were blocked using the broad band DA antagonist α-
flu within the PVTABLA and the PVTANASh pathway respectively. The present 
study provides dose dependent evidence for CB1R activation and blockade within the 
PVTA, and it’s dependence on DA neurons to execute its modulatory effects. Our 
findings present a functional relationship between CB1R and DA within the mesolimbic 
system. Furthermore, our results indicate that dose dependent pharmacological 
manipulations can result in both rewarding and aversive signals, depending on the area of 
projection. 
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5.1 SUMMARY OF FINDINGS 
5.1.1 Cannabinoid Transmission in the mPFC Controls Opiate Signaling  
Chapter 2 explores the role of CB1 transmission within the mPFC in relation to opiate 
reward using an unbiased classical conditioning paradigm. Cannabinoid, dopamine (DA), 
and opiate receptor pathways play an integrative role in emotional learning, associative 
memory, and sensory perception. Modulation of cannabinoid CB1 receptor transmission 
within the mPFC regulates the emotional valence of both rewarding and aversive 
experiences. Furthermore, CB1 receptor substrates functionally interact with opiate- 
related motivational processing circuits, particularly in the context of reward-related 
learning and memory. Considerable evidence demonstrates functional interactions 
between CB1 and DA signaling pathways during the processing of motivationally salient 
information. However, the role of mPFC CB1 receptor transmission in the modulation of 
behavioral opiate-reward processing is not currently known. Given the functional 
interaction between cannabinoids and opiates in establishing place preference 
conditioning and attenuating morphine self administration (Chaperon, Soubrié, Puech, & 
Thiébot, 1998; Navarro et al., 2001), we hypothesized that activation of CB1 receptors 
within the mPFC would potentiate the rewarding effects of a sub-threshold dose of 
morphine, that under normal circumstances does not produce any effects.  
Our findings however, indicated an opposite effect to our initial expectations. We found 
that activation of CB1 receptors intra-mPFC using a synthetic CB1 agonist made both a 
sub and supra reward threshold dose of morphine highly aversive. In contrast, inhibiting 
CB1 receptors by micro-infusing a synthetic CB1 antagonist intra-mPFC potentiated the 
rewarding effects of a subthreshold dose of morphine, while having no effects on the 
suprathreshold dose of morphine. Blocking DAergic projections from the VTA to the 
mPFC, blocked our observed reward and aversion signals, indicating that they are indeed 
DA dependent. We further explored the μ-opioid receptor, which has been shown to be 
excitatory, and the κ-opioid receptor which has been shown to be inhibitory (Ford, Mark, 
& Williams, 2006). Blockade of μ-opioid receptor intra-VTA, blocked the earlier 
potentiation of the subthreshold dose of morphine observed with intra-mPFC CB1 
antagonist. Conversely, blocking the κ-opioid pathway by micro-infusing a κ-opioid 
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receptor antagonist intra-VTA resulted in the ability of the CB1 agonist to potentiate the 
sub reward threshold dose of morphine, and the earlier observed morphine aversion was 
no longer present.  
Hence we report that CB1 modulated intra-mPFC opiate motivational signaling is 
mediated through a dissociable μ-opiate receptor dependent reward pathway, or a κ-
opiate receptor dependent aversion pathway, directly within the VTA. Our results provide 
evidence for a novel CB1-mediated motivational valence switching mechanism within 
the mPFC, controlling dissociable subcortical reward and aversion pathways (Ahmad, 
Lauzon, de Jaeger, & Laviolette, 2013). 
5.1.2 Bi-directional Cannabinoid Signaling in the BLA Controls 
Rewarding and Aversive Emotional Processing 
Functional connections between the BLA and NAc are involved critically in opiate-
reward processing. In the BLA, inhibitory GABAergic substrates are inhibited by 
cannabinoid CB1R activation and can modulate BLA projections to various limbic 
regions, including the NAc. High frequency activity in BLA efferents can modulate 
neuronal activity in the NAc via activating both DA and NMDA receptors (Floresco, 
Blaha, Yang, & Phillips, 2001). However the potential role of CB1R transmission in the 
regulation of opiate-related memory formation via the BLANAc circuit is not 
understood. Using an unbiased conditioned place preference paradigm (CPP) in rats, we 
examined the effects of intra-BLA CB1R modulation by either direct pharmacological 
activation (using CB1 agonist WIN 55,212-2) or blockade of CB1R transmission (using 
CB1 antagonist AM 251). We report that intra-BLA CB1R activation switches normally 
rewarding effects of morphine into strongly aversive effects. In contrast, CB1R blockade 
strongly potentiates normally sub-reward threshold effects of morphine. Next, using 
targeted microinfusions of an NMDA receptor antagonist to either the core (NACo) or 
shell (NASh) sub-divisions of the NAc, we found that selective blockade of NMDA 
transmission in the NA shell, but not core, prevented both intra-BLA CB1 blockade-
mediated opiate reward potentiation and CB1 activation-mediated aversion effects.  
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Finally, using multi-unit, in vivo electrophysiological recordings in the NASh, we report 
that the ability of intra-BLA CB1R modulation to control opiate reward salience and 
motivational valence is associated with distinct reward or aversion neuronal activity 
patterns and bi-directional regulation of intra-NASh fast-spiking interneurons (FSI) vs. 
medium spiny neurons (MSN). These findings identify a unique mechanism whereby bi-
directional BLA CB1R transmission can regulate opiate-related motivational processing 
and control affective states through functional modulation of mesolimbic neuronal 
activity. 
5.1.3 Cannabinoid Related Reward and Aversion Signals in the Posterior 
VTA is Mediated through DAergic Projections to the BLA and 
NASh 
The ventral tegmental area (VTA) has functional DAergic projections to the basolateral 
amygdala (BLA), and nucleus accumbens (NAc). It is a critical neural region responsible 
for mediating both rewarding and aversive related behavioural processing and 
cannabinoids are known to modulate the activity of the dopamine (DA) neuronal 
populations within the VTA. Previous research has shown that cannabinoid activation via 
THC administration in the posterior region of the VTA (PVTA), produced rewarding 
behavioural effects, while the same activation in the anterior region of VTA (AVTA), 
produced no effects (Zangen, Solinas, Ikemoto, Goldberg, & Wise, 2006). Hence, a 
functional dissociation between posterior and anterior VTA does exist. Using an unbiased 
conditioned place preference (CPP) procedure combined with behavioural pharmacology, 
we administered either a CB1 agonist (WIN-55,212-2) or antagonist (AM 251) into the 
PVTA or AVTA of Sprague-Dawley rats. CB1R activation in the PVTA with WIN 
55,212-2 (50-500ng) produced a dose-dependent cannabinoid reward CPP, while 
blockade of CB1R with AM 251 (50-500ng) produced a dose-dependent aversion. 
Interestingly, when WIN 55,212-2 and AM 251 were micro-infused in the AVTA, no 
cannabinoid reward or aversion effects were observed. To examine the PVTABLA and 
PVTANAc pathways, we used the broad spectrum DA receptor antagonist α-
flupenthixol to block DA transmission in either the NAc or BLA. Intra-BLA micro-
infusions of α-flu (1μg), blocked the earlier observed cannabinoid reward CPP, but not 
the cannabinoid antagonist-related aversion. Conversely, intra-NASh micro-infusions of 
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α-flu (1μg), blocked the aversion observed with intra-PVTA CB1 antagonist 
administration, but not the rewarding effects of intra-PVTA WIN-55. Thus, our findings 
demonstrate a functional dissociation between PVTA DA outputs to either the NASh or 
BLA. Furthermore, while the rewarding effects of intra-PVTA CB1 activation depend 
upon a PVTABLA pathway, the aversive effects of CB1 receptor blockade depend 
upon PVTA DA outputs to the NASh.  
5.1.4 Limitations 
The current available literature on receptors of interest such as CB1 and DA are often 
investigated in isolation. The brain is a complex structure, with a multitude of activated 
neuronal pathways and release of various neurotransmitters simultaneously. Thus, a 
significant limitation to our study is that we are unable to account for the coexistence and 
release of other neurotransmitters. For example: the mPFC, NAc and VTA are all rich in 
serotonin receptors that may have overlapping signaling pathways with DA. Hence, 
although we have accounted for cannabinoid transmission modulating DA levels, we did 
not account for the possible co-release of other neurotransmitters such as serotonin. In 
vivo electrophysiological studies have shown that activation of serotonin receptors 
increases DA activity levels (Prisco, Pagannone, & Esposito, 1994), and CB1R is co-
expressed in high density with both DA and serotonin receptors (Hermann, Marsicano, & 
Lutz, 2002). It is plausible to consider that CB1, DA, and serotonin receptors may 
concurrently interact with one another in the VTA, NAc, or mPFC, modulating their 
downstream effects through cyclic AMP and other signaling cascades, suggesting an 
alternative explanation to emotional processing mechanisms.  
The bi-directional effects of CB1 transmission observed in our study are all DA-
dependent, since using a broadband DA antagonist often blocked both the reward and 
aversion signals. Thus, another limitation to the study is that we did not differentiate 
between D1 and D2 receptor subtypes. In opiate naïve animals, activation of D1 receptor 
subtype has shown to potentiate the rewarding effects of opiates. However, when opiate 
dependence was achieved, potentiating the rewarding effects of opiates was switched to a 
D2 receptor subtype (Lintas et al., 2012). Therefore, it is important to differentiate 
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between the D1/D2 subtypes, in order to better understand the underlying mechanisms of 
the DAergic reward pathway. 
5.2 Conclusion 
Cannabinoids are one of the most abundant receptors in humans. Disruptions in CB1 
levels are implicated with many neuropsychiatric disorders, addiction studies, and deficits 
in learning and memory. The goal of this thesis was to characterize CB1 transmission in 
the mesolimbic reward circuitry in relation to the motivational effects of opiates. We 
explored the mPFC, BLA, VTA, and NAc circuitry. Our findings indicate novel bi-
directional CB1 mediated mechanism in the mPFC, and BLA with functional 
interconnections to the VTA and NASh that control opiate signaling. These results will 
contribute to the growing body of research concentrated on the biphasic characteristic of 
cannabinoids and further help elucidate their role in reward related learning. 
5.3 FUTURE DIRECTIONS 
Although our research has been successful in characterizing CB1 transmission in the 
mesolimbic pathway, many critical questions remain. It is important to note that our 
current results are dose dependent, and two doses of 50 and 500ng of CB1 agonist and 
antagonist were used. We should incorporate a mid range dose of 100ng for both CB1 
agonist WIN 55,212-2 and antagonist AM 251 to determine a more comprehensive dose 
curve. 
Furthermore, future studies are required to more precisely characterize the mechanism by 
which intra-BLA CB1R transmission may regulate DA release patterns within the NAc. 
For instance, intra-NAc D1 vs. D2 receptor subtypes have been reported to differentially 
regulate activity states of MSN vs. FSI neuronal subpopulations and drug-reward related 
behaviours (Smith et al., 2013; Calipari et al., 2016). Activation of intra-NAc D1-
containing MSN neurons has been demonstrated to promote reward-related behaviours 
whereas activating D2-containing MSN’s have been shown to oppose these effects and/or 
induce aversive effects. While beyond the scope of the present study, future studies using 
selective blockade of D1 vs. D2 MSN neuronal subpopulations may yield additional 
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insights into how BLA CB1R-dependent signaling may control accumbens processing of 
reward vs. aversion-related motivational signals. 
Next, although our posterior VTA reward findings parallel those of Zangen et. al. (2006), 
further studies are required to determine the neuronal pathways taken by the CB1 
antagonist mediated aversive signals and CB1 agonist mediated reward. Since 
cannabinoid and opiate receptors mediate overlapping pharmacological responses, it 
would be beneficial to examine the μ and κ-opioid receptor pathway in terms of 
cannabinoid reward and aversion signals. It is quite possible that the CB1 and opioid 
receptors can interact directly with one another, modulating each other’s function when 
co-expressed in the same cell. To test this theory, we would activate the CB1R and block 
the μ-opioid receptor pathway by intra-PVTA simultaneous micro-infusions of WIN 
55,212-2 and the μ-opioid receptor antagonist cyprodime. If our cannabinoid related 
reward is via the μ-opioid reward pathway, we would expect a block in the observed 
reward CPP. Conversely to explore the possibility of the CB1 related aversion in relation 
to κ-opioid inhibitory pathway, we would micro-infuse simultaneously intra-PVTA, the 
CB1 antagonist AM 251 and the κ-opioid receptor antagonist nor-binaltorphimine. 
Similarly, if the CB1 related aversion observed is mediated by the κ-opioid pathway, we 
would expect to see no CPP or CPA. 
Lastly, to further explore the role of CB1 transmission in the mPFC in mediating DA 
levels in the VTA, we can employ single cell in vivo electrophysiological recordings in 
the VTA to examine firing levels of DA at various doses of CB1 microinfusions for both 
rewarding and aversive signals. 
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